A Genetically Driven Immunologic Mechanism Underlying the Link between EBV and Multiple Sclerosis

Yoshiaki Yasumizu[1,†,*], Namkwon Kim[1,†], Cyprien A. Rivier[1,2,†], Jeonghyeon Moon[1,†, ‡], Shohei Kojima[3,†], Heng-Le Chen[1], Nicholas Buitrago-Pocasangre[1], Andrew Silberfeld[1,2], Elizabeth Quinn[1], Stephen Vaughn[1], Annalisa Morgan[1], Shufan Huo[1,2], Tomokazu S. Sumida[1], Kazuyoshi Ishigaki[3,4], Erin E. Longbrake[1], Guido J. Falcone[1,2,*], David A. Hafler[1,6,7,*]

[1] Department of Neurology, Yale School of Medicine, New Haven, CT, 06510, USA

[2] Yale Center for Brain and Mind Health, Yale School of Medicine, New Haven, CT, 06510, USA

[3] Keio University Human Biology-Microbiome-Quantum Research Center (WPI-Bio2Q), Tokyo, 160-8582, Japan

[4] Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, 160-8582, Japan

[5] Laboratory for Human Immunogenetics, Riken Center for Integrative Medical Sciences, Kanagawa, 230-0045, Japan

[6] Department of Immunobiology, Yale School of Medicine, New Haven, CT, 06510, USA

[7] Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA

[†] Equal Contributions

[‡] Current address: Dental and Life Science Institute, School of Dentistry, Pusan National University, Yangsan, 50612, Republic of Korea.

[*] Correspondence

Abstract

Epstein–Barr virus (EBV) is implicated as a trigger of multiple sclerosis (MS), yet the host genetic mechanisms linking EBV activity to MS is unknown. We performed a cross-ancestry genome-wide association study of EBV DNA positivity (N=617,186), identifying 39 susceptibility risk loci that significantly overlapped with MS risk genes (p=1.3×10^{-12}). Using our single-cell method for EBV detection, we identified 1,069 EBV-infected B cells across 38 individuals. EBV was predominantly in the latent phase and B cell receptor analysis revealed that memory B cell differentiation is altered by infection. Notably, EBV-infected switched memory and atypical B cells upregulated cytokines and costimulatory signals that influence T cell activation, and B cell signaling pathway. Finally, EBV-infected memory B cells upregulated risk genes from both the EBV and MS, suggesting that EBV-infected B cells link T cell modulation to activation of MS susceptibility pathways. These findings define a genetically driven immunologic mechanism underlying MS.

Introduction

Multiple sclerosis (MS) is the most frequent central nervous system (CNS) disease of young adults. The disease most commonly begins with an autoimmune, relapsing remitting phase mediated by circulating autoreactive T cells[1] that migrate to the central nervous system (CNS) and induce a marked inflammatory response both in the white matter and cortical grey matter. A secondary, neurodegenerative disease course occurs in a significant number of patients, presumably triggered by the initial T cell-mediated autoimmune process. As with other autoimmune disorders, MS is triggered by environmental interactions in genetically susceptible individuals. Indeed, we have identified 233 common genome loci associated with disease risk and one variant associated with disease progression.[2–4] The majority of these map to the immune system, targeting T cells, regulatory T cells, and, in particular, B cells.[2,5,6] As a result, MS patients exhibit a spectrum of immunopathology, including a skewing of T cells toward pro-inflammatory Th1 and Th17 programs,[6–8] loss of regulatory T-cell function with secretion of IFNγ,[9,10] and activation of B cells.[11]

Compelling epidemiologic data implicates Epstein–Barr virus (EBV) as the initiating event breaking immune tolerance in genetically susceptible individuals. A large longitudinal study of U.S. military personnel reported that EBV infection occurs before MS development[12] , indicating that EBV is a necessary causal factor for MS. Serum neurofilament light chain, a marker of axon injury, begins to rise only after EBV seroconversion. Moreover, MS patients exhibit higher EBV activity,[13–15] increased frequencies of EBV-reactive T cells[16,17], and EBV-derived antigens that cross-react with myelin antigens [18–20]. EBV primarily infects B cells, directly influencing their function[21], and we have observed distinctive alterations in B-cell phenotypes in MS (*manuscript in preparation*). Importantly, B-cell depletion therapy is a highly effective treatment for the early relapsing remitting, autoimmune phase of MS,[22] underscoring the central role of B cells in disease pathogenesis.

EBV plays a causal role in several other human diseases. Epidemiologic and immunologic evidence links EBV to non-Hodgkin lymphoma, including Burkitt lymphoma, nasopharyngeal carcinoma, gastric carcinoma, and, as discussed above, to MS, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE).[23] Although EBV infection is ubiquitous, affecting more than 90% of the global population, its clinical manifestations vary widely. In most individuals, EBV infection remains asymptomatic or latent, whereas a subset of subjects develops infectious mononucleosis or chronic active EBV infection. Moreover, infectious mononucleosis is not only a symptomatic form of EBV infection but also a strong epidemiological risk factor for MS.[24] However, few individuals develop malignancies or autoimmune diseases after EBV infection. This variability suggests that the host's ability to

control EBV reactivation differs among individuals, potentially due to underlying genetic
factors.[25]

EBV activity can be assessed through two major biomarkers: anti-EBV antibodies and
EBV DNA levels. Immunoglobulin (Ig) G targeting EBV antigens reflects prior exposure.
Over 90% of healthy adults and nearly 100% of patients with MS are seropositive.[15,26] In
contrast, circulating EBV DNA provides a more direct readout of viral persistence,
reactivation burden, or reservoir dynamics; blood EBV DNA has been reported to be
elevated in patients with MS and SLE.[14,27] Circulating EBV DNA is also clinically useful for
nasopharyngeal carcinoma screening.[28] These complementary biomarkers therefore capture
distinct aspects of EBV biology and may reveal different dimensions of host genetic control.

Genome-wide association studies (GWAS) have enabled the identification of host
genetic variants influencing susceptibility to infection-related traits and pathogen burden. For
example, analysis of HIV viral load overcame the limited resolution of infection-status GWAS
and identified key loci in the HLA and *CCR5* regions.[29] Recent advances in sequencing
technologies now allow simultaneous quantification of host and viral genomes from the same
dataset. Our group previously developed *VIRTUS*,[30] a pipeline for detecting viral transcripts
from RNA-seq data, and EBV detection from bulk RNA-seq has also been reported by
others.[31] Similar WGS-based approaches have recently been applied to the human blood
virome, including a GWAS of human herpesvirus 6 (HHV-6) viral load that revealed
integration sites and links to SLE disease activity.[32] For EBV, prior host-genetic studies have
largely focused on serologic antibody titers,[33] which capture infection history rather than
DNA-based measures of viral activity. More recently, population-scale WGS studies have
demonstrated that EBV-derived reads can be quantified in large biobanks and that host
genetic determinants, particularly within the MHC, contribute to variation in EBV DNA
detection and persistence. These studies establish the feasibility of EBV DNA GWAS at a
biobank scale while motivating the need to define how these signals extend across ancestry
groups and connect to disease-relevant cellular phenotypes. [34–36]

Here, we analyzed 617,186 participants from the All of Us Research Program[37] and the
UK Biobank[38] using harmonized viral-detection and quality-control pipelines across
ancestries and performed a cross-ancestry meta-analysis of EBV DNA positivity and viral
load. We extend this framework by jointly analyzing EBV DNA positivity and viral load,
integrating phenome-wide association studies (PheWAS), polygenic risk score (PRS)
analyses, Mendelian-randomization (MR)-based analyses, and HLA and *ERAP2*
interpretation to examine the shared host-genetic architecture linking EBV activity to human
disease (Fig. S1). Combining these population-scale analyses with single-cell RNA-seq
(scRNAseq) and spatial transcriptomic analyses, we identified specific cell types and

anatomical niches involved in EBV control. Notably, using *VIRTUS3*, we successfully
identified EBV-infected cells from people with MS and characterized their genetic effects.
Together, these findings provide a multi-ancestry genetic and cellular framework for host
control of EBV activity. By integrating cross-ancestry host genetics with single-cell analysis
of EBV-infected B cells in people with MS, our study links population-scale EBV DNA signals
to disease-relevant cellular states and offers a mechanistic context for EBV-associated
autoimmunity, elucidating a potential molecular mechanism underlying the cause of MS.

Results

EBV DNA detection from WGS

To detect EBV reads in WGS datasets, we developed an analysis pipeline that filters
and counts reads mapped to the EBV decoy sequence in the human reference genome. We
applied our pipeline to the diverse cohort of study participants enrolled in the All of Us
Research Program. After quality control, 409,331 individuals were included. DNA information
was obtained from two sources: whole blood (N=359,796) and saliva (N=48,086). EBV DNA
was detected in 20.8% of blood samples and 52.7% of saliva samples. Age, sex, and
ancestry were significantly associated with EBV positivity. In both blood and saliva, higher
age was strongly associated with higher detection rates (Fig. 1A, blood: *OR*=1.16 per 10
years, 95% *CI*=1.15–1.16, $p < 1 \times 10^{-100}$; saliva: *OR*=1.10 per 10 years, *95% CI*=1.09–1.11,
$p < 1 \times 10^{-65}$). Female sex was associated with a lower rate of EBV positivity compared with
males (Fig. 1A, blood: *OR*=0.83, *95% CI*=0.81–0.84, $p < 1 \times 10^{-100}$; saliva: *OR*=0.78, *95%*
CI=0.75–0.81, $p < 1 \times 10^{-35}$).

When examining ancestry, Europeans had the lowest EBV positivity, whereas all other
ancestries showed significantly higher odds ratios of EBV presence. In blood, African
(*OR*=2.17, $p < 1 \times 10^{-100}$), Latino/admixed American (*OR*=2.02, $p < 1 \times 10^{-100}$), East Asian
(*OR*=1.47, $p=9.2 \times 10^{-43}$), Middle Eastern (*OR*=1.31, $p=1.2 \times 10^{-4}$), and South Asians
(*OR*=1.29, $p=6.1 \times 10^{-11}$) ancestries had significantly higher odds ratios relative to Europeans
(Fig. S2A). In saliva, African (*OR*=1.61, $p=4.1 \times 10^{-65}$), Latino/admixed American (*OR*=2.02,
$p < 1 \times 10^{-100}$), East Asian (*OR*=1.94, $p=5.8 \times 10^{-32}$) and South Asian ancestries also showed
increased odds (*OR*=1.42, $p=1.4 \times 10^{-5}$) (Fig. S2A). Middle Eastern ancestry showed a trend
for higher EBV positivity in saliva but did not reach statistical significance (*OR*=1.32,
$p=0.078$).

Next, we examined the distribution of EBV DNA load. When normalized by the number
of reads mapped to the human genome, the EBV DNA load was on average 3,826-fold
higher in saliva compared to blood (Fig. 1B). Moreover, a subset of individuals carried viral
loads that far exceeded the population average. Indeed, in blood, the top 1% of samples
accounted for 64% of the total EBV DNA load, with the top 5% and 10% contributing 83%

and 91%, respectively. In saliva, the skew was even more pronounced: the top 1%
accounted for 80%, the top 5% for 94%, and the top 10% for 97%. To statistically evaluate
this trend, we approximated the distribution with a generalized Pareto distribution (GPD). A
positive shape parameter (ξ) indicates a heavy-tailed distribution (Fig. 1B). In blood, ξ was
estimated as 0.92 (95% *CI*:0.86–0.98) at the 95th percentile threshold, while in saliva, ξ was
even larger at 1.15 (95% *CI*:1.04–1.25). Varying the threshold from the 90th to 99th
percentiles yielded consistently positive ξ values, confirming the robustness of these results.
These findings demonstrate that the distribution of EBV DNA load is heavy-tailed in both
blood and saliva, suggesting the presence of a small number of super-carriers who
contribute disproportionately to the overall viral burden.

To comprehensively investigate diseases co-occurring with EBV infection, we
conducted a Phenome-wide Association Study (PheWAS). Using European-ancestry
participants from All of Us, we performed a PheWAS of EBV DNA positivity and viral load
(Figs. S2B, C, Supplementary Tables 1 and 2). As recently reported,[35] we confirmed that
both EBV DNA positivity and viral load showed strong associations with immunosuppressive
conditions such as HIV infection and post-transplant immunosuppression, as well as with
tobacco use and chronic obstructive pulmonary disease (COPD).[39] Furthermore, the
analysis identified a significant association with infectious mononucleosis, a manifestation of
primary EBV infection in adolescents. Unexpectedly, neither MS nor SLE emerged as
positively associated traits (MS: EBV positivity, *OR*=0.83, *FDR*=0.034; viral load, *FDR*=0.78.
SLE: EBV positivity, *FDR*=0.27; viral load, *FDR*=0.96). In addition to confirming known
associations with rheumatoid arthritis, we observed correlations with encephalitis,
encephalopathy, and polyneuropathies, suggesting links to other inflammatory neurological
diseases. Although more traits were significantly associated with EBV DNA positivity
(*FDR*<0.05, 475 traits) than with EBV viral load (270 traits), the viral load analysis
specifically highlighted associations with virus-related malignancies such as non-Hodgkin
lymphoma and T cell lymphoma, as well as myopathy. The PheWAS results not only
reproduced well-established associations between EBV and related diseases, validating our
analytical pipeline, but also revealed broader links to autoimmune and inflammatory
disorders, underscoring the extensive disease spectrum influenced by EBV infection.

Multi-Ancestry genome-wide association study of EBV DNA
We applied a similar pipeline to the UK Biobank, in which WGS was performed using
DNA derived from whole blood. EBV-derived DNA was detected in 15.5% of UK Biobank
samples. We then performed a cross-ancestry GWAS combining UK Biobank samples with
blood-derived samples from the All of Us cohort. We selected 5,020,877 SNPs with a minor
allele frequency (MAF) of ≥1% in All of Us (Methods). Association tests were performed

using Regenie[40] in all ancestry groups from the All of Us Research Program and in
European participants from the UK Biobank. A European meta-analysis was conducted
using METAL[41] (N=493,312), and a cross-ancestry meta-analysis (European from UK
Biobank and European, African, and Latino/Admixed American from All of Us) was
performed using MR-MEGA[42] (N=617,408) (Supplementary Table 3). In the cross-ancestry
analysis, we identified 39 genome-wide significant loci associated with EBV positivity and 16
loci associated with viral load (Figs. 1C, S3A, Supplementary Tables 4-6). Using LD score
regression (LDSC),[43] the SNP-based heritability (h^2) of EBV positivity was estimated at
1.77% (*SE*=0.22%), while that of viral load was 1.24% (*SE*=0.18%). There was a positive
genetic correlation between EBV positivity and EBV viral load (*rg*=0.71, *p*=4.08x10^{-24}). We
observed a slight inflation of test statistics in the cross-ancestry meta-analysis, particularly
for the binary trait (Fig. S3B, EBV positivity, λ_{GC}=1.15; viral load, λ_{GC}=1.07). Importantly, the
λ_{GC} values from each individual GWAS were well controlled (λ_{GC}<1.08 in all cases,
Supplementary Table 3). We evaluated whether the MHC contributed to the inflation;
removing this region yielded comparable values (EBV positivity, λ_{GC}=1.14; viral load,
λ_{GC}=1.06). Of note, in the LDSC analysis, intercepts were low (EBV positivity, *intercept*=1.04;
viral load, *intercept*=1.03), indicating that the observed inflation is likely due to polygenicity
rather than residual confounding.

Next, we examined the lead SNPs within each locus in detail. Outside of the HLA region,
approximately half of the associated variants were intronic (Supplementary Table 4,
positivity: 63.1%; viral load: 53.3%), and roughly half were located in cis-eQTLs
(Supplementary Table 4, positivity :55%; viral load: 60%). The majority of these loci
(Supplementary Table 4, positivity: 65.8%; viral load: 60%) have been previously implicated
in immune-related traits, including MS, SLE, RA, IgM levels, and blood cell counts in prior
GWAS (Fig. 1C). Remarkably, there was a significant overlap with genetic variants
associated with MS risk (Fig. 1D, *OR*=32.1, *p*=1.3x10^{-12}) and severity (Fig. 1D, *OR*=180.6,
p=7.54x10^{-3}) including MS susceptibility alleles, *HLA-DRB1*04:04, *HLA-A*02:01 and to a
lesser extent, *HLA-DRB1*15:01. Specifically, among the top hits, 29.7% of the EBV
positivity-associated genes and 33% of the viral load-associated genes overlapped with
genes reported in our MS GWAS, including *DYSF*, which has been associated with MS
severity[4] (Figs. 1C and S4A). When we examined the direction of effects for EBV DNA
positivity across autoimmune diseases, we found that a number genetic variants, including
SLAMF7, *CTLA4*, *EOMES*, *CD86*, *TP63*, *TRAF3*, *CLEC16A*, *RSBN1,* and *IKZF3* showed
concordant effects, with increased EBV DNA positivity associated with increased disease
risk, while *SP140*, *SH2B3*, and *PTPN11* exhibited discordant directions of effect with less
EBV DNA presence (Fig. 1C). The genes highlighted by the GWAS provided biological
insights into the regulation of EBV activity. For example, *TERT*, encoding the catalytic

subunit of telomerase, emerged as one of the top hits. Indeed, the top variant within this
locus, rs7726159, is associated with telomere length[44] (Supplementary Table 5, Fig. S4B).
Given that EBV is known to drive telomerase regulation to promote immortalization of
infected cells,[45] this finding may highlight a mechanistic link between EBV replication and
telomere biology. We also observed strong support for biologically plausible genes, including
IFI16, a nuclear DNA sensor that restricts herpesvirus reactivation, and *SP140*, a PML-
nuclear body component involved in antiviral chromatin regulation by repressing type I IFN
responses (Fig. S4C).[46–48]

Stratified LD score regression[49] revealed that genetic heritability for both EBV DNA
positivity and EBV DNA load was concentrated in transcriptionally active genomic regions,
particularly at transcription start sites (TSS; enrichment=23.4±4.1 [positivity], 31.3±5.3 [load]),
FANTOM5 enhancers (19.9±10.3 [positivity], 32.7±13.8 [load]), and coding regions (17.2±5.2
[positivity], 17.0±6.3 [load]), indicating that genetic variants influencing EBV control tend to
localize to regulatory and coding elements with high transcriptional activity (Fig. S4D).
Pathway enrichment analysis revealed that EBV susceptibility loci were primarily
concentrated in immune response–related pathways (Fig. S4E, Supplementary Tables 7 and
8). Both EBV positivity and EBV DNA load showed significant enrichment for T cell activation,
CD8$^+$ αβ T cell activation, and T cell proliferation, reflecting a shared involvement of
cytotoxic T cell–mediated immune responses. Cell cycle G1/S phase transition was
specifically enriched for EBV positivity, while EBV DNA load additionally involved epithelial-
associated pathways such as positive regulation of keratinocyte proliferation and
multiciliated epithelial cell differentiation, indicating potential contributions of epithelial cell
proliferation and differentiation to viral load regulation.

To assess the effects of GWAS-prioritized host genes on EBV transcriptional activity,
we performed siRNA-mediated knockdown of candidate genes and analyzed EBV
transcripts (Fig. 1F). Knockdown of EBV DNA GWAS-prioritized host genes altered EBV
transcriptional activity and, at 72 hours, was associated with a shift toward reduced EBV
gene expression (Figs. 1G and S6). This was more pronounced for lytic-associated
transcripts than for latent-associated transcripts. Consistent with this pattern, for example,
SP140 knockdown reduced *BLLF1* expression, whereas *PARP15* knockdown decreased
LMP2 and *BMRF1*. However, these effects were not uniform, including a transient increase
in latent transcripts after *IKZF3* knockdown and increased *EBNA2* expression at 72 hours
after *PARP15* knockdown. Together, these findings suggest that EBV DNA GWAS hit genes
contribute to the regulation of EBV transcription, but their effects are not simply binary; rather,
they act in a transcript-selective and time-dependent manner, with a broader repressive
trend emerging at later time points.

To further test the causal relationship between EBV and autoimmune diseases, we
performed bidirectional Mendelian randomization using 27 independent SNPs associated
with EBV DNA positivity (Fig. S5A, Supplementary Tables 9). Genetically predicted EBV
DNA positivity was associated with increased risk of MS (OR=1.45, 95% CI=1.18–1.80), RA
(OR=1.27, 95% CI=1.05–1.54), and SLE (OR=1.44, 95% CI=1.08–1.91), but not ischemic
stroke, used as a negative control. These effects were predominantly driven by MHC
variants, and reverse MR analyses did not support an effect of autoimmune disease liability
on EBV DNA levels. Together, these results support a unidirectional contribution of
genetically determined EBV activity to autoimmune disease risk, largely mediated by MHC
variation.

To investigate whether the polygenic architecture of EBV activity contributes to
autoimmune disease risk, we constructed PRSs from the EBV DNA GWAS in the European
ancestry subset of the All of Us cohort and tested them in European ancestry participants in
the UK Biobank (N=487,181; 2,423 MS cases; Fig. S5B, Supplementary Tables 10). A one–
standard deviation increase in the EBV DNA positivity PRS was associated with increased
risk of MS (OR=1.11, 95% CI=1.07–1.16, p<0.0001), with individuals in the top PRS decile
showing higher MS prevalence than those in the bottom decile (0.68% vs 0.52%; OR=1.33,
95% CI=1.13–1.57). Partitioning the PRS revealed that this association was largely driven by
variants within the MHC region, whereas non-MHC variants showed no significant effect.
Together, these results indicate that host genetic variation shapes EBV activity, with a
substantial contribution from immune regulatory loci and the MHC region, linking genetically
determined EBV control to autoimmune disease susceptibility.

Polygenic risk scoring and EBV DNA measured by quantitative PCR (qPCR)
To evaluate whether identified genome-wide significant risk loci for EBV DNA capture
biologically meaningful variation in viral load, we assessed PRSs in an independent cohort
with qPCR-based measurement of EBV DNA. We calculated PRSs based on risk variants
identified in the meta-analysis of European ancestry using PRScs.[50] We evaluated
association with EBV DNA positivity measured by qPCR in an independent Yale cohort of
European ancestry (Fig. 1E, S5C, and Supplementary Tables 11; *N*=94; mean age
40.2±14.7 years; 71% female). EBV DNA positivity was 2/10 (20%) in the top decile, 1/74
(1.4%) in the middle group, and 0/10 (0%) in the bottom decile for both positivity and viral
load PRS (Ordinal trend tests positivity: *p*=0.024; viral load: *p*=0.016). Consistently, one
standard deviation increase in the PRS was associated with a higher EBV DNA load after
adjustment (log10 EBNA1 copies/mL) (positivity: *β*=0.21, *SE*=0.076, *p*=0.006; load: *β=0.26*,
SE=0.075, *p*=0.0009). When we stratified variants by their location inside or outside the
MHC region, only the PRSs derived from the MHC region showed significant associations

with qPCR-confirmed EBV DNA positivity and load, while PRSs constructed from variants
outside the MHC region showed no significant associations. Taken together, these findings
demonstrate that qPCR-measured EBV DNA levels in our independent cohort closely track
with the polygenic architecture identified by our EBV DNA GWAS, supporting the validity and
biological relevance of the GWAS results.

Antigen presentation by HLA and EBV activity

The strongest associations in both GWASs were located within the HLA locus. In
addition, a secondary genome-wide significant signal was identified at rs27300, a variant
residing within a linkage disequilibrium block encompassing the *LNPEP* and *ERAP1/2* genes
(Figs. 2A and S6A). This variant exhibited a significant eQTL effect on *ERAP2* expression in
lymphoblastoid cell lines (LCLs) (p=2.33x10^{-118}, Fig. 2B), but not with *LNPEP* (p=7.07x10^{-6},
Fig. 2B). *ERAP2* encodes an aminopeptidase essential for peptide trimming selectively
during antigen presentation via MHC class I molecules. This allelic directionality provides
additional support for a functional role of *ERAP2* in EBV control. The *ERAP2*-increasing C
allele corresponds to the protective direction in the EBV GWAS, suggesting that more
efficient peptide trimming enhances antigen presentation and improves the clearance of
EBV-infected cells.

We also investigated the associations with HLA alleles and amino acid usage and EBV
susceptibility. Using All of Us participants of European ancestry, classical HLA alleles were
imputed with SNP2HLA,[51] and their associations with EBV activity (DNA positivity and DNA
viral load) were examined. In both traits, *HLA-DRB1**04:04 showed the most significant
association. After conditioning analysis, the top alleles associated with EBV DNA positivity
were *HLA-DRB1**04:04, *B**14:02, *A**02:01, *DQA1**05, and *B**35:01, while those for EBV DNA
load were *HLA-DRB1**04:04, *A**02:01, *B**35:01, *DQA1**05:01, and *B**14, showing a broadly
consistent pattern between the two traits (Fig. 2C and S6B, 7, 8, Supplementary Tables 12,
13). While to a lesser degree, EBV DNA positivity was also seen with the strongest MHC
associated allele, *DRB1**15:01. Furthermore, an amino acid–level association analysis
identified multiple residues significantly correlated with EBV activity (Figs. 2C, S6B, S7, S8,
and Supplementary Tables 14, 15). Notably, valine at position 95 of *HLA-A**02:01 (A95V),
detected in both positivity and viral load analyses, was located within the F pocket of the
peptide-binding groove, while position 30 of HLA-DRB1 (L/R/Y variants), detected in the viral
load analysis, was located in the P7 pocket (Fig. 2D). Both residues are situated within key
structural regions that determine peptide-binding specificity, suggesting that EBV-associated
HLA signals may reflect functional variation in peptide-binding pockets influencing viral
antigen presentation and immune recognition.

Finally, we performed a detailed characterization of ERAP2 function. ERAP2
preferentially trims peptides bearing R/K at the N-terminus, resulting in the exposure of
downstream residues such as F/Y/W at the N-terminus. Consistent with this, re-analysis of
immunopeptidome data[52] under ERAP2 perturbation reproduced a similar N-terminal motif
(Fig. S6C). These results indicate that the effect of ERAP2 may not be restricted to specific
viral antigens but broadly shapes the peptide repertoire, while potentially contributing to the
presentation of a subset of EBV-derived antigens. Taken together, these findings suggested
that antigen presentation is a key component of EBV regulation and a hotspot of
susceptibility.

Tissue-, Cell-, and Niche-Specific Heritability Analyses

To elucidate the biological contexts underlying host control of EBV activity, we
performed partitioned heritability analysis using stratified LD score regression (S-LDSC),[53]
which infers tissue-level enrichment based on external functional annotations. Both EBV
positivity and EBV DNA load exhibited marked enrichment in immune-related tissues (Fig.
S9A). For EBV positivity, significant heritability enrichment was observed in spleen,
peripheral blood, lymph nodes, synovial fluid, and lung, suggesting that systemic and
mucosal immune environments contribute to host susceptibility to EBV activity. In contrast,
EBV DNA load showed its strongest enrichment in EBV-transformed lymphocytes, followed
by spleen, lymphoid tissue, and blood, indicating a link between viral load regulation and B
cell transformation processes.

We next sought to interpret the polygenic signals identified in the EBV GWAS in the
context of specific cell types and spatial niches using integrated single-cell and spatial
transcriptomic analyses. We first applied single-cell disease relevance score (scDRS)[54] to
single-cell RNA-seq data from PBMCs of EBV-positive and control individuals,[55] analyzing all
cell types jointly. This analysis revealed enrichment of EBV-associated polygenic signals in
cytotoxic lymphocyte populations, including CD8 effector memory T cells, NK cells, and $\gamma\delta$ T
cells (Fig. S9B).

Using the same dataset, we then focused the analysis on B-cell lineages that are
directly involved in EBV infection. The dataset included publicly available single-cell RNA-
seq profiles from patients with infectious mononucleosis and hemophagocytic
lymphohistiocytosis (HLH). Existing pipelines based on Cell Ranger remove overlapping
reads, resulting in substantial loss of reads from the compact EBV genome, and they may
misalign reads with sequence similarity to human transcripts.[56] To overcome these
limitations, we developed VIRTUS3, an analysis framework optimized for viral detection in
single-cell data (https://github.com/yyoshiaki/VIRTUS3). In this workflow, reads are first
aligned to the human genome using Cell Ranger. Unmapped reads are then recovered and

re-aligned to viral genomes using Alevin. This pipeline can filter out reads with stringent

similarity to the human genome, and manipulate the reads aligned to multiple genes on viral

genomes. This approach enabled the detection of 1.84-fold more EBV-positive cells

compared with conventional methods (Figs. 3A-C). EBV-positive cells were predominantly

detected among plasmablasts, followed by B memory and B intermediate cells, whereas

naïve B cells showed almost no EBV positivity (Fig. 3D). Using scDRS, we further evaluated

the cell-type–specific distribution of EBV DNA-associated polygenic scores. In memory B

cells, polygenic scores were significantly elevated in EBV-positive compared with EBV-

negative cells ($p=3.0\times10^{-5}$), while no difference was observed in plasmablasts (Figs. 3E and

S9C). These findings indicate that host genetic control of EBV activity is exerted primarily

within the memory B-cell compartment rather than at the terminally differentiated

plasmablast stage.

We next investigated the immune microenvironments in which host genetic factors

regulating EBV activity are concentrated by applying scDRS-spatial, a spatial heritability

framework we previously developed[57]. At the tissue level, polygenic signals showed the

strongest enrichment in lymph nodes and tonsils, confirming that these lymphoid tissues

represent major sites of EBV regulation (Fig. S9D). We then analyzed the spatial localization

of genetic signals within tonsillar tissue, a key reservoir for EBV infection, latency, and

reactivation. Polygenic signals for both EBV DNA positivity and viral load were highly

enriched within the germinal center, T:B border, and proliferating follicle regions, which are

immune niches characterized by active B cell responses and dynamic B–T cell interactions

(Figs. 3F–H and S9E). These findings indicate that host genetic factors controlling EBV

activity act predominantly within lymphoid microenvironments supporting T cell–dependent B

cell activation. In particular, the germinal center and T:B border emerge as key

immunological niches where genetic variation may influence EBV persistence and immune

control.

EBV DNA detection in blood from MS patients

We next examined whether EBV DNA levels are directly associated with MS by qPCR.

We compared whole-blood EBV DNA positivity between treatment-naive MS patients and

non-MS individuals collected at the Yale MS Center. EBV DNA was detected in 11.5 percent

of MS patients (27/234) and 5.26 percent of controls (9/171), showing a higher proportion in

MS (Fig 4A; OR=2.35, p=0.0033, tested by two-sided Fisher's Exact Test). To more

rigorously assess this association, we conducted a meta-analysis of 11 studies

encompassing 1,740 individuals and 525 EBV DNA–positive events (Figs. 4A, S10, and

Table S16. The fixed-effect model yielded an odds ratio of 1.85 (95% CI=1.48–2.33,

p<0.0001), and the random-effects model produced a nearly identical estimate (OR=1.85,

95 % *CI*=1.39–2.45, *p*=0.0007). Heterogeneity was low (I^2 = 11.0 percent), indicating
consistent effects across studies. Although the effect size in MS is more modest than in
other autoimmune diseases such as SLE or RA, where odds ratios typically range from 3.5
to 5,[27,58] well-controlled case–control comparisons consistently demonstrate higher
circulating EBV DNA in MS. This pattern reinforces the concept that EBV activity is modestly
elevated around the time of clinical MS onset, but critically, it is important to note that this
does not give insight into EBV activity at the time of initial infection when the virus may
trigger disease initiation many years before clinical manifestation of CNS lesions.

Single-cell resolution cellular dynamics in EBV-infected B cells in people with
MS

We next sought to directly characterize the interaction between EBV infection and MS-
related genetic programs by performing single-cell analyses of PBMCs from MS and healthy
individuals with EBV detection at single-cell resolution. A comprehensive survey of public
scRNA-seq datasets revealed virtually no EBV-positive cells.[59] This was unlikely to reflect a
true biological absence but rather a technical limitation of conventional single-cell RNA-seq,
which captures only polyadenylated transcripts and therefore fails to detect the major latent
EBV noncoding RNA *EBER1*, which lacks a polyA tail. To overcome this limitation, we
introduced a spike-in probe enabling specific capture of *EBER1*, which is a similar approach
to EBV-seq.[60] Yet even with this improved method, EBV-infected cells remained exceedingly
rare, with none detected in PBMCs (0 of 51,950 cells from 3 donors) and only three cells
detected in tonsils (3 of 134,073 cells from 12 donors) from both healthy donors and MS
patients, underscoring a fundamental limitation of single-cell approaches when the infected
population is extremely sparse (Fig. S13).

Previous studies have shown that blood EBV DNA load strongly correlates with the
number of *EBER1*-positive cells,[61] suggesting that EBV DNA–positive samples may enable
the recovery of EBV-infected cells at single-cell resolution. We therefore analyzed banked
frozen PBMCs from EBV–positive individuals screened by qPCR analysis. We again
performed single-cell RNAseq with the *EBER1* spike-in probe, prioritizing EBV DNA–positive
MS and non-MS samples (Fig. 5A). With this technique, we could detect 1,069 DNA–positive
cells from 470,989 B cells (0.23%) (Figs. 5B and C, Supplementary Table 17). As expected,
the number of EBV–positive cells were positively correlated with qPCR-based EBV DNA
load (*rho*=0.55, *p*=5.0×10^{-4}, Fig. 5D). The EBV–positive cells were predominantly memory B
cells, antibody-secreting B cells (AbSCs), naive B population expressing Type 1 interferon
signature genes (Bnaive MX1), and ASC precursor naive B cells (Figs. 5E and S14B).
Notably, most of the EBV–positive cells expressed latent EBV genes, including *EBER1,*
LMP-1, and LMP-2A, while some antibody-secreting B cells expressed lytic genes even in

high EBV DNA load individuals (Figs. 5E and S14B). Interindividual variation was observed
in the distribution of EBV-positive cells (Fig S14B). For example, some individuals showed
enrichment in switched memory B cells (Bsm cells) and ASCs, others in T-bet[+] CD11c[+]
Atypical B cells (atBCs), and others in naive B cells and ASCs, indicating several distinct
distribution patterns. In most EBV–positive cells, the transcriptional program was dominated
by latent EBV genes. However, in a subset of individuals, cell populations expressing
BARF0 and *A73* were observed, and a few individuals also harbored rare cells expressing
early lytic genes.

EBV also affected BCR characteristics (Figs. S14B-D). Somatic hypermutation was
increased in EBV–positive cells in Bnaive MX1 and Bmem intermediate (Bmem int). *IGHG3*
and *IGHG1* were more frequent, and *IGHM, IGHD, and IGHA2* were less frequent. EBV–
positive cells tended to be more expanded, especially in Bnaive MX1, Bmem int, atBCs, and
AbSCs. Clonal analysis identified multiple clones derived from the germline BCR sequence
containing EBV-positive cells (Fig. 5F and G). These clones showed diverse cellular
compositions, including clones enriched for atBCs and Bmem int, clones composed almost
entirely of AbSCs, and clones consisting of both AbSCs and memory B cells. Integrative
analysis showed the differentiation pattern observed in conventional EBV-negative clones, in
which intermediate B cells progressed through unswitched memory B cells toward memory B
cells, was not evident in EBV-positive clones. In contrast, shared clonal relationships linking
atBCs to switched memory B cells were relatively prominent among EBV-positive clones.
These findings suggest that, although the distribution of EBV-infected cells varied across
individuals, EBV transcription in peripheral blood was dominated by latency-associated
genes, and EBV infection may influence B-cell states and differentiation trajectories.

Next, we examined how EBV-positive B cells alter their transcriptional programs.
Pathway analysis revealed marked upregulation of BCR signaling, NF-κB signaling, antigen
processing and cross presentation in memory B cells and viral mRNA translation in antibody-
secreting cells (Fig. 6A, Supplementary Table 19). Importantly, focused analysis of cytokines
and receptors involved in immune interactions (Fig. 6B) showed increased expression of
IL12A and *IL23A* in EBV-infected memory B cells, which promote Th1 and Th17
differentiation, together with reduced expression of the immunoregulatory cytokine *IL10* and
its receptor *IL10RA*. EBV-positive cells also upregulated *IL16, IL6ST* (gp130), and *IL6R*,
molecules implicated in MS pathogenesis. While *CXCR4* was downregulated, molecules
involved in recruiting and activating pathogenic T-cell subsets, including *CCR6* (Th17-
associated) and *CXCR3* (Th1-associated), were also increased. In addition, EBV-positive
cells showed elevated expression of receptors crucial for B-cell differentiation and survival,
including *CXCR5*, *TNFRSF13B* (TACI), *TNFRSF13C* (BAFF-R), *TNFRSF14* (HVEM), and

TNFRSF17 (BCMA), several of which have prior genetic links to MS. Finally, Bmem int and
Bsm upregulated T-cell help molecules, including *CD40*, *CD86*, and *HLA class I and class II*.
Together, these findings suggest that EBV-infected memory B cells may contribute to
immune tolerance breaking by promoting Th1/Th17 polarization while weakening regulatory
immune circuits.

Finally, we investigated how host genetic factors interact with EBV infection across B-
cell subsets. Using scDRS to evaluate EBV GWAS signals, we found that the EBV DNA
positivity–associated polygenic signal was significantly enriched in EBV-positive B naïve and
switched memory B cells, whereas no meaningful enrichment was observed in antibody-
secreting cells (Fig. 6C). These findings suggest that early infection responses in naïve B
cells and persistent infection in switched memory B cells represent key cellular contexts in
which EBV regulation is exerted. We then performed a similar analysis using MS onset–
associated gene sets. Polygenic scores for MS were markedly elevated in EBV-positive
unswitched memory B cells and switched memory B cells, while antibody-secreting cells
showed a reduction in MS-related signal (Fig. 6C). Specifically, MS risk gene expression
was increased within EBV-infected cells in Bnaive, atBCs, and memory B cells, indicating
that EBV-infected B cells constitute a biological context where MS risk genes are
preferentially engaged. Notably, many MS susceptibility genes, EBV susceptibility genes,
and shared loci between the two GWAS, including *HLA class I and II* molecules, *IKZF3*,
SP140, *CD86*, *TRAF3, and CLEC16A*, showed increased expression in EBV-positive
switched memory B cells (Fig. 6D). These observations indicate that EBV infection activates
a gene network that intersects with MS susceptibility specifically within defined B-cell
subsets. Taken together, these results demonstrate that EBV infection enhances both viral
polygenic signals and MS susceptibility gene expression in select B-cell subsets, revealing a
cellular setting in which viral regulation and autoimmune genetic risk converge.

Discussion
Here, we developed a pipeline to quantify EBV DNA from whole-genome sequencing
data and applied it to population-scale cohorts. A cross-ancestry GWAS of EBV DNA
positivity in 617,186 individuals identified 39 susceptibility risk loci. We validated this finding
in our independent cohort and found that qPCR-confirmed EBV DNA-positive individuals
were markedly enriched in the top decile of EBV polygenic risk scores containing these
newly discovered loci. Intriguingly, there was a significant overlap with genetic variants
associated with MS, RA, and SLE susceptibility alleles, and Mendelian randomization
analyses further supported a causal influence of EBV activity on MS, largely driven by HLA
variation. By establishing a single-cell RNA-seq method optimized for *EBER1* detection, we
found that EBV RNA was detected primarily in memory, atypical, and antibody-secreting B

cells, with interindividual heterogeneity. Notably, EBV was predominantly in the latent phase
even in high EBV DNA load individuals. BCR lineage analysis revealed that memory B cell
differentiation is altered by infection. EBV-infected memory B cells, including switched
memory B cells strongly upregulated cytokines and risk genes from both the EBV and MS
GWAS. These data demonstrate that EBV–infected B cells are a key modulator of T cells
and that MS susceptibility genes are preferentially activated within EBV-infected B cells (Fig.
6E). This identifies a genetic and immunologic mechanism by which EBV infection leads to
pathologic activation of B cells in a genetically susceptible individual, driving the multitude of
immune dysfunctions observed in MS with subsequent initiation of disease.

MS is the autoimmune disease for which EBV is most strongly implicated as a
necessary environmental factor, and both tissue and cell specificity of EBV regulation further
align with MS-specific immunobiology in which memory B cells drive CNS infiltration.[62]
Moreover, it has been clearly demonstrated that the EBV virus harbors sequences that are
cross-reactive with myelin epitopes, including GlialCAM and anoctamin-2, that are likely also
playing a critical role in the pathogenesis of MS[18–20]. Thus, EBV uniquely may drive
activation of myelin-reactive T cells both by breaking immune tolerance and by presenting
cross-reactive antigens.

Although EBV DNA showed no positive association with MS in our PheWAS,[63] a well-
controlled treatment-naive MS cohort and the case-control meta-analyses showed elevated
EBV DNA levels in MS patients. This discrepancy is likely explained by the time course of
EBV involvement in the onset of MS. Specifically, EBV seroconversion occurs an average of
7.5 years before clinical onset,[12] MS diagnosis requires CNS lesions disseminated in time
and space,[64] and a prodromal period precedes diagnosis.[65] As a result, EBV load at the time
of diagnosis is likely to be partially deflated. Furthermore, individuals with MS in cohorts such
as All of Us include patients receiving long-term immunotherapy and those many years after
diagnosis, making it difficult to capture EBV activity during the true initiation phase. These
considerations highlight the importance of examining newly diagnosed, treatment-naïve
patients or MS high-risk individuals prior to disease onset to accurately evaluate EBV activity
in early MS.

Recent population-scale studies established the feasibility of quantifying EBV DNA from
WGS data and highlighted genetic factors for controlling EBV persistence.[35,36] However, the
relationship between EBV activity and MS appears to depend on the level of genetic
resolution being examined. At the broad polygenic level, the association with MS was
modest, consistent with our own observations that diffuse genome-wide correlation is
limited.[36] By contrast, when focusing on lead EBV-associated loci, we observed clear
overlap with established MS susceptibility loci. One plausible explanation is that the

relationship between EBV control and MS is not captured by a uniform genome-wide effect,
but rather by a more selective set of shared loci with heterogeneous directions of effect. We
therefore view prior studies and our results as complementary: earlier work defined the
general host-genetic architecture of EBV persistence, whereas our study identifies a more
specific overlap at highlighted loci and further localizes that convergence to EBV-infected B-
cell states using single-cell and spatial transcriptomic analyses.

Our large-scale WGS analysis also clarified the broader epidemiology and biology of
EBV infection across populations. In the United States, individuals of African, Latino/admixed
American, and Asian ancestry showed higher EBV positivity rates, consistent with serology-
based findings.[66] Female individuals showed lower EBV DNA positivity despite a higher
prevalence of autoimmunity. This pattern suggests that sex differences in EBV susceptibility
and the host immune response to EBV may shape autoimmune risk. We also found that a
small subset of "super-carriers" accounted for a disproportionate fraction of EBV DNA
detected in the population.

Cross-ancestry GWAS clarified the host genetic architecture underlying EBV activity.
Strong enrichment of associations in the HLA region, in T-cell–related pathways including
association in *CTLA4*, *EOMES*, and *CD86*, and at the T–B border of secondary lymphoid
tissues, underscores the central role of B cells in antigen presentation to T cells in EBV
regulation. EBV employs multiple immune-evasion strategies, including BNLF2a-mediated
inhibition of TAP1.[67] Here, we showed that HLA polymorphisms shape antigen presentation
efficiency and directly influence EBV activity. *HLA-DRB1**04:04, a known risk allele for RA
and MS,[68,69] and an allele that presents myelin-specific TCRs in MS patients,[70] was
associated with higher EBV activity. The risk allele *HLA-DRB1**15:01 was also associated
with higher EBV antigen presentation, though to a lesser extent than the *HLA-DRB1**04:04
allele, suggesting other factors contribute to the genetic risk associated with these MHC
haplotypes.   In contrast, *HLA-A**02:01 was associated with reduced EBV activity and is
protective against MS[71] and EBV⁺ Hodgkin lymphoma.[72] HLA molecules shape antigen-
presentation preferences and thymic TCR repertoire formation.[73] In addition, components of
the antigen-processing pathway, including *ERAP2*, emerged as important regulators of EBV
control. The reanalysis of immunopeptidomic data indicates that *ERAP2* is a key regulator of
peptide presentation via MHC class I and EBV clearance. *ERAP2* allotype is also associated
with MS susceptibility.[74] Our findings indicate that HLA diversity and related genes exert
strong effects on EBV susceptibility and that several EBV-associated alleles overlap with
autoimmune risk alleles, suggesting shared genetic pathways linking EBV control and
autoimmunity.[75] Moreover, PRS and MR analysis highlighted the HLA contribution to
autoimmune diseases, including MS.

Non-HLA loci further underscore that EBV regulation relies heavily on intrinsic programs

of the host B cell. Genes in which the direction of effect was concordant between EBV DNA

positivity and autoimmune disease risk, including *RSBN1*, *SLAMF7*, *CTLA4*, *EOMES*, *CD86*,

TP63, *TRAF3*, *CLEC16A*, and *IKZF3*, converged on pathways governing B-cell

differentiation, germinal-center dynamics,[76] NF-κB signaling,[77] T cell effector function, and

antigen presentation. This pattern suggests that B-cell differentiation and activation

programs provide a shared biological foundation that simultaneously promotes EBV

persistence and increases autoimmune susceptibility. In contrast, genes showing discordant

effects, such as *SP140*, *SH2B3* and *PTPN11*, map to pathways involved in

immunoregulatory thresholds and negative feedback, raising the possibility that trade-offs

between antiviral responsiveness and autoimmune risk underlie their opposing directions of

effect. Representative loci also suggested plausible mechanisms of EBV control: SP140 and

IFI16 are linked to viral genome surveillance and restriction of viral gene activation,[78–80]

whereas TERT suggests a role for telomere biology in EBV replication and long-term

survival of infected B cells. Together, these loci highlight a second layer of EBV control,

intrinsic B-cell programs that operate in parallel with HLA-mediated antigen presentation.

Building on these findings, we further leveraged three key advances: improved single-

cell detection of viral transcripts, an optimized bioinformatics pipeline, and sample

prioritization based on EBV DNA by qPCR, to achieve the direct identification of EBV-

infected cells in patients with MS at single-cell resolution. By analyzing a large cohort

enriched for untreated, newly diagnosed MS cases, we were able to capture EBV-positive

cells during the clinically relevant early phase of disease. These infected cells were

concentrated within B switch memory cells, atBCs, and ASCs. The predominance of latency-

associated EBV transcripts suggests that latent-phase viral programs may be particularly

relevant to MS-related immune dysregulation. Indeed, LMP1 and LMP2A are known to

mimic or rewire CD40 and B-cell receptor signaling, respectively, and EBNA2 binds MS

susceptibility loci in a genotype-dependent manner.[81] This is consistent with the observation

that EBV-positive cells showed altered B-cell differentiation trajectories. Atypical B cells have

recently emerged as an important component of MS immunopathology,[82,83] although their

persistence and developmental fate remain context-dependent.[84] In our data, shared clonal

relationships between atBCs and B switched memory cells were relatively prominent among

EBV-positive clones, suggesting that EBV infection may support the persistence of an atBC-

associated program or facilitate its transition into longer-lived switched memory states.[85]

EBV-infected B cells showed a coordinated activation of MS genetically mediated

immune communication pathways, including upregulation of *IL12A* and *IL23A*, which drive

Th1 and Th17 differentiation. IL-12 has been shown to diminish Treg suppressive capacity in

inflammatory settings, shifting the balance toward effector responses.[86] This pro-
inflammatory shift was further reinforced by reduced expression of *IL10* and its receptor
IL10R, consistent with impaired regulatory B-cell function described in MS.[87] EBV-positive
cells also increased *IL16*, *IL6ST* (gp130), and IL6R, molecules implicated in MS
pathogenesis, and upregulated the chemokine receptors *CCR6* and *CXCR3*, which position
B cells within Th17- and Th1-rich inflammatory niches rather than homeostatic environments.
In parallel, EBV-positive B cells showed elevated expression of receptors crucial for B-cell
differentiation and survival, including *CXCR5*, *TNFRSF13B* (TACI), *TNFRSF13C* (BAFF-R),
TNFRSF14 (HVEM), and *TNFRSF17* (BCMA). The upregulation of *CD86*, *CD40*, and *HLA*
class I/II also supports the enhanced T cell help. Together, these findings indicate that EBV
infection rewires B-cell immunobiology that is enhanced by genetic variants associated with
risk of MS by enhancing T-cell help, promoting positioning within inflammatory niches, and
reinforcing B-cell differentiation and survival programs relevant to MS.

Notably, both MS susceptibility genes and EBV activity–associated genes were highly
expressed within these EBV-infected memory B cells. This represents the first direct
evidence that host genetic risk for MS and genetic determinants of EBV activity converge
within EBV-infected memory B cells. Given that memory B cells serve as potent, antigen-
specific professional antigen-presenting cells, targeting this compartment provides a
compelling biological rationale for the remarkable efficacy of B-cell–depleting therapies in
MS.

Epidemiologic studies indicate that there is an approximately seven-year lag between
EBV infection and the clinical onset of MS, and before there are clinical symptoms, patients
are experiencing new, intermittent MRI lesions. This raises the question as to whether EBV
is the initial trigger of disease, or viral reactivation leads to disease flare-ups later in the
disease, or both. We hypothesize a mechanism by which EBV infection in genetically
susceptible adolescents leads to a highly intense, acute activation of myelin-reactive T cells
where overexpression of key immune pathways or "danger signals" in B cells, again
mediated by the genetic architecture as demonstrated here, breaks immune tolerance in a
stochastic manner, leading to a cascade of events initiating autoimmune MS.

Taken together, our work identifies the epidemiology of EBV across ancestries and
elucidates the genetic basis of EBV B cell expression. By integrating multiple omics data, we
mapped the key immunological "hotspots" where this regulation occurs. These findings
support the existence of shared biological pathways linking EBV to autoimmune diseases,
including MS. Notably, EBV-infected memory B cells and atypical B cells upregulated
cytokines and costimulatory signals that influence T cell activation, IFNγ secreting Tregs, and

regulators of B cell differentiation and survival, enhanced by MS susceptibility genes. EBV-
infected memory B cells upregulated risk genes from both the EBV and MS GWAS,
suggesting that EBV-infected B cells constitute a critical hub that modulates T cell responses
while simultaneously activating MS susceptibility pathways within the B cell compartment.
Together, these findings define a definitive genetic and cellular framework elucidating the
potential molecular mechanisms causing MS.

Data and code availability

GWAS summary statistics will be available at the GWAS Catalog and PGS Catalog upon acceptance. Locusplot for all lead SNPs and the adjacent region is available at 10.6084/m9.figshare.30712496. Single-cell RNAseq data generated in this study will be deposited in GEO and CZ CELLxGENE upon acceptance. Code generated for this work will be publicly accessible on GitHub upon acceptance. The pipeline used for EBV DNA detection from WGS is available at https://github.com/shohei-kojima/WGS_EBV_search. VIRTUS3 is available at https://github.com/yyoshiaki/VIRTUS3. All codes used for the analysis will be available on github (https://github.com/yyoshiaki/EBV_MS_2025_Manuscript) upon acceptance.

Author contributions

Conceptualization, Y.Y., S.K., K.I., C.R., and D.A.H; data analysis, Y.Y., C.R., S.K., N.K., and H.L.C.; experiment, N.K. and J.M.; data curation and sample collection, L.Q., S.H., A.S., N.B.P, A.M. and E.E.L.; writing, Y.Y., N.K., C.R., S.K., E.E.L., G.J.F. and D.A.H.; supervision, Y.Y., T.S.S., K.I., E.E.L., G.J.F., and D.A.H.; funding acquisition, Y.Y., D.A.H., and G.J.F.

Competing interests

Conflict of interest: DAH has received research funding from Bristol Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Repertoire Inc., Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno Therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. EEL has received research support from Biogen, LabCorp, Intus, and Genentech. She has been a consultant for Bristol Myers Squibb, EMD Serono, Genentech, Sanofi Genzyme, and NGM Bio. AM has been a consultant for Genentech.

Acknowledgement

This work was supported by NIH grants (P01 AI073748, U19 AI089992 U24 AI11867, R01 AI22220, UM 1HG009390, P01 AI039671, P50 CA121974, and R01 CA227473); the Race to Erase MS (to DAH); the National MS Society (to DAH and EEL); Department of Defense (HT9425-24-1-0522 to EEL); the Common Mechanisms in Autoimmunity Insight Award jointly funded by Breakthrough T1D, the Lupus Research Alliance, and the National MS Society (to YY), and Robert E. Leet and Clara Guthrie Patterson Trust Mentored Research Award, Bank of America, Private Bank, Trustee (to YY). YY is supported by JSPS Overseas Research Fellowships. NK is supported by the Sejong Science Fellowship (Overseas) from the National Research Foundation of Korea (RS-2024-00342077). CR is supported by an AAN/AHA Ralph L. Sacco Scholars Fellowship (AHA.24RSSPOST1328228), a Pilot Grant from the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine (P30AG021342), a Pilot Award from the Yale Center for Brain and Mind Health,

691 and a generous gift from the Paul and Sandra Montrone from the Penates Foundation. The
692 illustrations were generated using BioRender.com.

Methods

Human Subjects

In this study, we analyzed whole-genome sequencing (WGS) data and linked electronic
health record information from participants enrolled in the All of Us Research Program and
the UK Biobank. All analyses were conducted in accordance with each data resource's
governance framework (All of Us: Registered Tier; UK Biobank: Application 58743), and only
authorized researchers accessed the data within secure computing environments. For All of
Us, WGS data derived from both blood and saliva were used, whereas UK Biobank provided
WGS data derived from blood DNA. In both cohorts, all datasets were de-identified, and no
personally identifiable information was available to researchers. Clinical information included
ICD-9/10 diagnosis codes, age, sex, self-reported ancestry, and laboratory measurements,
limited to variables approved for research use within each biobank.

A cohort of individuals at increased risk for MS was recruited at Yale University. This cohort
study consists of (1) family members of MS patients and (2) asymptomatic individuals
incidentally discovered to have morphologically suspicious lesions on brain MRI. Participants
donate biospecimens and are prospectively followed. European-ancestry cohort members
were selected for PRS analysis. A cohort of patients with MS used for qPCR and scRNAseq
was also recruited at Yale School of Medicine.

EBV DNA quantification from WGS

The human reference genome, GRCh38, which is used in AoU and UKB, contains the EBV
decoy sequence, named chrEBV. To detect EBV reads in WGS samples, we investigated
reads mapped to chrEBV stored in the CRAM files. A WGS sample can sometimes contain
very abundant EBV reads due to viremia and have the potential to cause a heavy
computational burden. To decrease the computational cost, samples with more than 350,000
reads mapped to chrEBV were randomly downsampled using samtools to 350,000 reads.
Reads were then filtered to retain only proper pairs, passing standard quality control metrics,
with duplicates, secondary, and supplementary alignments removed. Mapping length was
calculated from the CIGAR string, and only reads with an aligned length of ≥145 bp were
retained. The EBV genome carries a repetitive region, named BamHI W repeat (positions
12,000–35,355 bp). EBV reads derived from this region can be multi-mapping due to the
repetitive nature of the BamHI W repeat region in the EBV reference genome. Our pipeline
accounts for this repetitive nature and avoids counting such multi-mapping reads repeatedly.
Finally, paired-end reads passing all filters were defined as EBV reads, and counts were
summarized separately inside and outside the BamHI W repeat. In the case of analysis with

downsampling, it estimates the number of EBV reads in the original CRAM file by accounting
for the downsampling ratio.

Association analysis of EBV DNA

We analyzed the association of EBV positivity with age_at_collection, genetically predicted
ancestry, which is provided by All of US, and sex. Observations with missing values were
excluded. Logistic regression (generalized linear model with binomial distribution and logit
link) was fitted separately for blood samples and saliva samples. The model was specified
as:

$$\text{logit}\{P(\text{EBVpos}=1)\} = \beta_0 + \beta_1 \cdot \text{age\_scaled} + \beta_2 \cdot \text{ancestry\_pred} + \beta_3 \cdot \text{sex}$$

To facilitate interpretation, age was scaled in 10-year units (age_scaled = age_at_collection /
10). European ancestry (eur) and male sex were used as reference categories. Robust
(HC3) standard errors were applied. Coefficients were reported as odds ratios (ORs) with
95% confidence intervals. Analyses were conducted in Python using the package
statsmodels. Logistic regression models were estimated using statsmodels GLM (Binomial,
logit) with robust HC3 standard errors.

Generalized Pareto distribution (GPD) analysis

To assess the tail behavior of EBV DNA distributions, we applied a peaks-over-threshold
(POT) approach using the Generalized Pareto distribution (GPD). Normalized EBV DNA
reads (normalized by the number of human-genome coverage) were used. For each sample
type (blood, saliva), the 95th percentile of the distribution was chosen as the threshold u,
and exceedances above u were modeled with the GPD parameterized by shape (ξ) and
scale (β). Parameter estimation was performed by maximum likelihood, and 95% confidence
intervals of ξ were obtained via profile likelihood. For conceptual illustration, simulated GPD
curves with ξ = -0.3, 0, 1.0, and a common scale were generated to highlight the difference
between finite, exponential, and heavy-tailed distributions.

Genotype Data Processing and Quality Control

Genotype data were processed independently for the All of Us Research Program[37] and the
UK Biobank,[38] following harmonized quality control procedures to enable cross-cohort
analyses. Unless otherwise noted, equivalent filters and thresholds were applied across both
datasets. The variant set for downstream analyses was defined based on the All of Us ACAF
PGEN callset and applied consistently to both cohorts.

For the analysis of All of Us, we utilized the All of Us ACAF PGEN callset, which includes
variants with "AF>1% or AC>100 in any ancestry," filtered using the FT flag. Participants
were excluded if DNA was derived from saliva, retaining only blood-derived samples.

Following previous studies, we removed individuals with immunodeficiency disorders (ICD-
10 codes D80–D89) or those with 'ID_057.1' (Human immunodeficiency virus infection) in
PhecodeX. Related and flagged individuals were excluded using the All of Us auxiliary files
(relatedness_flagged_samples.tsv and flagged_samples.tsv). We retained only samples with
inferred sex chromosomes XX or XY, sex at birth recorded as male or female, and available
age-at-collection information.

Variant-level quality control was performed per ancestry with the following parameters: MAF
between 0.01 and 0.99, Hardy–Weinberg equilibrium (HWE) $p>1\times10^{-\square}$ (using keep-fewhet),
biallelic variants only, and a genotype missingness rate <5%. An ancestry-specific variant list
was generated for each group, and the union across all ancestries and cohorts was used for
subsequent analyses.

For the UK Biobank cohort, EBV DNA was quantified from WGS data using the same
pipeline as All of Us, counting reads mapping to the EBV reference genome (chrEBV). EBV
read counts were normalized by mean sequencing coverage and log10-transformed
(log10[normalized reads + 1]) for the quantitative trait analysis; a binary EBV DNA positivity
variable was defined as having at least one EBV-mapped read. Sample-level quality control
included: retention of individuals of European genetic ancestry based on the UK Biobank
genetic ethnicity field (Data-Field 22006); exclusion of one member from each pair of related
individuals (*kinship coefficient*≥0.0442) using the UK Biobank relatedness file; exclusion of
individuals with sex chromosome aneuploidy or discordance between reported and genetic
sex; removal of WGS preparation plates with unusually high EBV positivity rates (>28%);
and exclusion of individuals in the top 1% of normalized EBV reads. As in All of Us, we
excluded individuals with immunodeficiency disorders (ICD-10 codes D80–D89) or HIV
infection (ICD-10 codes B20–B24), as well as those taking immunosuppressant medications
at baseline (Data-Field 20003). Principal components were computed on unrelated
European individuals and projected onto all European samples. For GWAS, we used
imputed genotype data from UK Biobank. For REGENIE Step 1, we used directly genotyped
variants after quality control (*MAF*≥0.05, *genotype missingness*<5%, *MAC*≥40, HWE
$p>1\times10^{-2\square}$, biallelic SNPs only) and LD pruning (window 200 kb, step 50 variants, $r^2<0.2$),
yielding 346,104 variants. For REGENIE Step 2 association testing, we applied filters of
MAC ≥ 40 and imputation INFO ≥ 0.8. For the meta-analysis, we restricted to the same set
of variants defined by the All of Us ACAF callset by matching on chromosome, position, and
alleles.

Genome-Wide Association Analysis and meta-analysis
Genome-wide association analyses were performed using REGENIE[40] with comparable
parameters across cohorts/population. In step 1, LD-pruned variants were selected using

ancestry-specific thresholds.[88] For individuals of African ancestry, we used --indep-pairwise
1000 100 0.15; for non-African ancestries, --indep-pairwise 1000 100 0.3. Covariates
included the first 20 principal components, sex at birth, and age at collection (including
quadratic and age×sex interaction terms), with additional cohort-specific covariates such as
sequencing batch metrics, fasting time, lymphocyte percentage, smoking status, time of
blood draw, and month of collection to account for technical and seasonal variation. Step 2
analyses were restricted to SNPs that passed QC in at least four of the six ancestry groups.
For the cross ancestry meta analysis, cohort/population with the participants more than
10,000 (European from UK Biobank and European, African, and Latino/Admixed American
from All of Us) were used. We performed the meta analysis using MR-MEGA, which
accounts for ancestry heterogeneity through genetic principal components.[42] For the meta-
analysis restricted to Europeans (UK Biobank + All of Us), METAL[41] was used with an
inverse-variance weighted fixed-effects model. The visualization and the selection of lead
SNPs were performed using gwaslab.[89] The annotation of lead SNPs was performed with
VEP,[90] OpenTable[91] and ImmuNexUT platform.[92]

LD Score Regression and Tissue-specific Heritability Analyses

We performed LDSC analyses to estimate SNP-based heritability and partition it across
tissue- and =cell-type–specific annotations.[43,49,53] GWAS summary statistics were derived
from a meta-analysis of the All of Us and UK Biobank European ancestry cohorts, combined
using METAL as described above. To ensure consistency, only HapMap3 (HM3) variants
were retained during harmonization. Reference LD scores and regression weights for
European populations were obtained from the Broad Institute's public Google Cloud
repository   (https://console.cloud.google.com/storage/browser/broad-alkesgroup-public-
requester-pays). Baseline model v1.2 annotations were used to account for known genomic
features.[49] For each trait, we estimated SNP heritability and genetic correlations using LDSC.
Tissue- and cell-type–specific heritability enrichment was assessed using LDSC (--h2-cts)
with Multi_tissue_gene_expr annotations.[53]

Pathway analysis

First,   we   performed   SNP   annotation   with   gene   locations   (NCBI37.3,
https://ctg.cncr.nl/software/MAGMA/aux_files/NCBI37.3.zip) and the reference data created
from   1000   genomics   Phase3   (g1000_eur,
https://ctg.cncr.nl/software/MAGMA/ref_data/g1000_eur.zip) using magma --annotate (with
the option, window=10,10).[93] For the pathway-level analyses, we used MAGMA v1.10 on the
same European-ancestry METAL meta-analysis summary statistics used for LDSC. SNPs
were first annotated to genes using NCBI37.3 gene locations with a ± 10 kb window and the
1000 Genomes Phase 3 European reference panel (g1000_eur) as the linkage

disequilibrium (LD) reference, and variants within the extended MHC region (chr 6: 25-34
Mb) were excluded. Gene-based association tests were then performed with MAGMA using
SNP-level p values and sample sizes while accounting for LD from g1000_eur, yielding
gene-level z statistics. These results were subsequently used for competitive gene-set
analyses that were carried out using MSigDB v2025.1 gene sets, including Hallmark, KEGG
canonical pathways, and Gene Ontology (biological process, molecular function, and cellular
component) collections.

PheWAS
We conducted analyses in individuals of European ancestry from the All of Us cohort. ICD-9
and ICD-10 codes were harmonized using PhecodeX.[94] The R package SPAtest was used
to perform score tests based on the saddlepoint approximation, and beta coefficients were
estimated using Firth's method. Visualization was performed with matplotlib.

EBV detection from scRNAseq data.
We developed a pipeline, VIRTUS3, to detect EBV transcripts from 10x Genomics scRNA-
seq data. First, we performed alignment to the human reference (GRCh38, refdata-gex-
GRCh38-2020-A) and cell barcode calling using Cell Ranger count. The resulting barcodes
were used as a whitelist for viral quantification. Unmapped reads were extracted from the
position-sorted BAM file with samtools view -f 4 and converted back to FASTQ with
cellranger bamtofastq. These unmapped reads were then quantified against an EBV
reference (NC_007605.1, B95-8 strain, CDS plus EBER1/2) using Salmon/Alevin [95] with the
barcode whitelist. The pipeline was applied to the 10x 3' data of PBMC from EBV-HLH, EBV-
IM, and healthy individuals.[55] We compared the number of EBV-positive cells by VIRTUS3
with the reported number in Suzuki *et al.*[55] In their analysis, EBV detection was performed
using Cell Ranger v5.0 with the custom reference made by the human genome (GRCh38)
and the genome of the EBV representative strain (NC_007605).

Polygenic signal enrichment analysis using scDRS and scDRS-spatial
The polygenic signals were calculated using scDRS[54] and scDRS-spatial.[57] The gene scores
derived from MAGMA were used. For PBMC scRNAseq data and the visualization of spatial
transcriptome data, we used imputed gene expression calculated by MAGIC.[96] For tissue-
and region-specific analysis, we used raw counts for scDRS. The validation of the usage of
MAGIC is described in our previous publication.[57] Polygenic enrichment for each cell was
calculated using scDRS (v1.0.3) with --n-ctrl 1000. We used the number of detected genes
per cell as a covariate. Group-level statistics were summarized using scdrs perform-
downstream and visualized with scdrs.util.plot_group_stats.

HLA typing and single-marker association testing

We followed the protocol described by Sakaue et al.[97] Briefly, we used the ACAF PGEN call set of European participants from the All of Us cohort. Sample quality control was performed as in the GWAS. Variant filtering was conducted using PLINK2[98] with the following options: --maf 0.005 --chr 6 --geno 0.1 --hwe 1e-10 --snps-only just-acgt --min-alleles 2 --max-alleles 2. Variants were lifted over to hg19 using CrossMap, and phasing was performed with EAGLE (v2.4.1).[99] HLA imputation was carried out using Minimac4 (v4.1.6)[100] with the publicly available 1KGP HLA panel (https://github.com/immunogenomics/HLA_analyses_tutorial). Single-marker association testing was performed with PLINK2 --glm, adjusting for age, sex, PC1, and PC2 as covariates. We also performed conditioning using PLINK2. The visualization of HLA structure was performed using PyMOL.

ERAP2-dependent peptide motif analysis

To assess the impact of ERAP2 on the immunopeptidome, we analyzed publicly available immunopeptidomics data (PXD024109[52]) generated from EBV-transformed lymphoblastoid cell lines (LCLs) with ERAP2 knockout using CRISPR-Cas9. W6/32 pan–MHC class I immunoprecipitation data were downloaded and used for downstream analysis.

For motif analysis, the first 9 residues from the N-terminus of each peptide were used, and peptides shorter than 9 amino acids were excluded. Amino acid frequencies across all peptides were defined as background. For ERAP2-dependent and ERAP2-sensitive peptide groups, position-specific amino acid frequencies were calculated. Peptides were classified based on log2 fold change (WT/KO), where ERAP2-dependent peptides were defined as log2FC ≥ 1 and ERAP2-sensitive peptides as log2FC ≤ –1. Motifs were visualized using logomaker.[101]

To quantify ERAP2-dependent sequence features, a sequence-based model was trained using the same dataset. Features included peptide length, amino acid composition, and position-specific one-hot encoding with right padding. A Ridge regression model was trained using these features to predict ERAP2-dependent effects, and the resulting model was used to compute an ERAP2 score for each peptide. As candidate EBV peptides presented on MHC class I peptides, the data generated by Nyeo et al.,[35] using NetMHCpan,[102] was used. As a human control dataset, HLA class I positive ligands were extracted from the IEDB database.[103]

siRNA-mediated knockdown and EBV quantification

JY cells were transfected with pooled siRNAs (three independent siRNAs per gene; Integrated DNA Technologies [IDT]; catalog numbers listed in Supplementary Table 20)

targeting six candidate genes. The GWAS highlighted genes that are expressed in JY cells
and B cells, and that achieved enough knockdown efficacy in the preliminary experiments
were selected as the target genes. A non-targeting siRNA was included as a control.
Electroporation was performed using a Lonza 4D-Nucleofector system with SG buffer and
program DS-137, according to the manufacturer's instructions. Following nucleofection, cells
were incubated at room temperature for 10 min before the addition of pre-warmed medium
and subsequent plating.

Cells were harvested at 24, 48, and 72 h post-transfection. Total RNA and genomic DNA
were simultaneously extracted using the AllPrep DNA/RNA 96 Kit (QIAGEN, 80311)
according to the manufacturer's instructions.

For transcript analysis, RNA was reverse-transcribed into cDNA, and EBV gene expression
was quantified by TaqMan-based qRT-PCR. Pre-designed TaqMan Gene Expression
Assays (Thermo Fisher Scientific) were used for host transcripts, whereas EBV-specific
primers and probes were synthesized by IDT. Expression levels were normalized to B2M,
and relative expression was calculated using the $2^{-\Delta\Delta Ct}$ method. Catalog numbers and
sequences of primer and probe are provided in Supplementary Table 20.

Genotyping using SNP microarray
We genotyped SNPs from individuals collected at Yale University using the Illumina Global
Diversity Array. The genotyping was performed at the Keck Microarray Shared Resource
core laboratory at Yale University. We performed standard quality control procedures;
variant-level filters included genotyping missingness <5%, MAF > 0.05, HWE p > $1x10^{-6}$.
Genetic ancestry was determined with principal component analysis using 1000 Genomes
as a reference panel. Samples of European genetic ancestry were imputed using IMPUTE 2,
and strand alignment was performed using SHAPEIT. SNPs with INFO > 0.7 and MAF >
0.01 were retained in the final genomic data.

Genotyping using Whole Genome Sequencing
We performed whole-genome sequencing on genomic DNA at the Yale Center for Genome
Analysis. DNA quantity, purity, and integrity were assessed by spectrophotometry, agarose
gel electrophoresis, and Qubit fluorometry. Libraries were prepared from 250 ng genomic
DNA using the Watchmaker DNA Library Prep Kit with xGen UDI-UMI adapters, quantified
by qPCR, and sequenced on the Illumina NovaSeq X Plus platform to generate 151-bp
paired-end reads, targeting at least 135 Gb of passing-filter data per sample. Sequencing
data were processed using the Sarek pipeline,[104] which utilizes GATK HaplotypeCaller.[105]

For a subset of samples, WGS-derived genotypes were harmonized to the imputed array
genotype dataset and merged with array-based genotypes for sample demultiplexing.

Mendelian Randomization Analysis

Two-sample Mendelian randomization (MR) was performed to assess potential causal
relationships between EBV DNA positivity and autoimmune diseases. Genetic instruments
for EBV DNA positivity were derived from the European-ancestry meta-analysis of EBV DNA
GWAS. Instruments were selected at genome-wide significance ($p<5\times10^{-8}$) and clumped
using PLINK-based LD clumping ($r^2<0.0001$, *window*=1000kb) with the European 1000
Genomes Phase 3 reference panel. SNPs with significant heterogeneity in the exposure
GWAS (HetPVal<0.05) were excluded prior to instrument selection. Outcome GWAS
summary statistics were obtained from publicly available sources: MS from the International
Multiple Sclerosis Genetics Consortium (IMSGC), RA from the European-ancestry GWAS,
SLE from published meta-analyses, and ischemic stroke from the MEGASTROKE
consortium (used as a negative control). Harmonization of exposure and outcome data was
performed using the genal Python package, with palindromic SNPs retained (action=1).
When exposure SNPs were not directly available in outcome datasets, proxy SNPs were
identified using LD-based searching ($r^2\geq0.6$, ±10kb window).MR analyses were conducted
using the inverse-variance weighted (IVW) method with random effects as the primary
analysis. Sensitivity analyses included the Weighted Median method and MR-PRESSO for
outlier detection and correction. MR-PRESSO[106] was applied when evidence of pleiotropy or
heterogeneity was detected (Cochran's Q p<0.0001, or discordant IVW and Weighted
Median estimates). When MR-PRESSO identified significant outliers, results were reported
after outlier removal. Causal estimates are reported as odds ratios with 95% confidence
intervals. To assess the contribution of the MHC region, instruments were stratified into
MHC-only (chromosome 6: 25–34Mb) and non-MHC variants, and MR analyses were
performed separately for each subset. Bidirectional MR was performed to test for potential
reverse causation, using genetic instruments for MS, RA, and SLE as exposures and EBV
DNA as the outcome.

Polygenic risk scoring

PRSs were constructed using PRScs[50] , a Bayesian continuous shrinkage method that infers
posterior effect sizes by integrating GWAS summary statistics with an external LD reference
panel. The final SNP set for each PRS was determined by the intersection of GWAS variants
with the reference panel, yielding 729,766 variants for the genome-wide scores. For stratified
analyses, MHC-only and no-MHC PRSs were derived by respectively retaining or excluding
variants within the HLA region on chromosome 6 (chr6:25–34 Mb, GRCh38).

For validation in the independent Yale cohort, we used GWAS summary statistics from the
European-ancestry meta-analysis (All of Us + UK Biobank) for EBV DNA positivity (binary
trait) and EBV DNA load (quantitative trait). The Yale cohort comprises European-ancestry
individuals at increased risk of MS (relatives of MS patients and those with morphologically
suggestive brain MRI lesions; N=94; mean age 40.2±14.7 years; 71% female) with
measured EBV DNA load by qPCR. PRS were calculated for each participant, then
standardized to mean 0 and SD 1. Participants were grouped into three PRS categories
based on cohort-specific percentiles (≤10%, 10–90%, and ≥90%). EBV DNA positivity was
modeled using Firth bias-reduced logistic regression with the PRS as either a continuous
predictor (per SD increase) or categorical variable (percentile groups), adjusting for age, sex,
and the first 10 genotype principal components. Ordinal trend tests across PRS categories
were obtained from models including an ordinal coding of the three groups. EBV DNA load
was analyzed using linear regression of log10-transformed EBV DNA copies/mL with the
same covariate sets.

For the UK Biobank MS association analysis, we used GWAS summary statistics from the
European-ancestry subset of All of Us only (to avoid sample overlap) to construct PRSs that
were then applied to European-ancestry individuals in the UK Biobank (N=487,181; 2,423
MS cases; 484,758 controls). PRS values were standardized and participants were grouped
by percentiles (≤10%, 10–90%, and ≥90%, or quintiles). Associations with MS were
assessed using logistic regression adjusted for age, sex, and the first 10 principal
components.

EBV detection by qPCR
Genomic DNA was extracted from whole blood (1-2mL) using the QIAamp DNA Blood Midi
kit (Qiagen, 51183), following the manufacturer's spin-column protocol. Briefly, blood was
incubated with a protease and lysis buffer at 70°C for 10 minutes, mixed with 100% ethanol,
and loaded onto the spin column. After centrifugation, columns were washed with AW1 and
AW2 buffers, and DNA was eluted with 300µL of elution buffer. DNA was stored at –80 °C
before analysis.

EBV genomic DNA was quantified by TaqMan qPCR targeting *BamH1W*. Reactions
contained DNA (5µL), Fast Advanced qPCR master mix (Applied Biosystems, 444457),
primers, and a FAM-labeled probe. qPCR was performed on a StepOnePlus (Applied
Biosystems) with the following cycling conditions: 95 °C for 20 s, followed by 40 cycles of
95 °C for 1 s and 60°C for 20 seconds. An EBV DNA standard (ATCC, VR-3247SD: 6.6×10^5
copies/µL; Lot: 70063234). Ten-fold serial dilutions of the standard (10^5 to 10^1 copies) were
prepared and run with each qPCR experiment to define assay sensitivity and ensure plate-
to-plate consistency. For each run, a standard curve was generated by plotting Ct values

against the log-transformed input copy numbers, followed by calculation of the correlation
coefficient (R^2) from the resulting linear regression.

Meta-analysis of EBV DNA in patient with MS and controls

We searched PubMed from inception to 2025 using predefined keywords ("multiple
sclerosis", "Epstein–Barr virus", "PCR", "viral load"). Only peer-reviewed original research
articles that examined EBV DNA in peripheral blood from both MS patients and healthy
controls using qPCR were included. Because the sensitivity of EBV DNA detection varies
across laboratories and assays, we restricted the analysis to studies in which EBV DNA
positivity in either group fell within the range of 5–75 percent to minimize the influence of
extreme outliers. When raw counts were not reported, the number of EBV-positive subjects
was estimated by multiplying the total sample size by the reported percentage and rounding
to the nearest integer. Meta-analysis of odds ratios was performed using the metabin
function implemented in the meta package in R.

Single-cell RNA-seq optimized for EBV detection

PBMCs were isolated from whole blood by density-gradient centrifugation using Lymphoprep
(STEMCELL, 18061) and cryopreserved in Bambanker Freezing Media (Bulldog-Bio, BB01)
for storage in liquid nitrogen until use. PBMCs were thawed rapidly, and B cells were
enriched from PBMCs using a pan-B cell isolation kit (STEMCELL, 19554) or B cell isolation
kit (STEMCELL, 19054) according to the manufacturer's protocols. Enriched B cells were
counted and adjusted to a final concentration corresponding to a target loading of 20,000
cells.

Tonsil cells were collected by needle aspiration. Collected samples were centrifuged at
500×g for 5 minutes to remove the supernatant, and the cell pellet was resuspended in 1mL
PBS. Total and leukocyte counts were determined using trypan blue and methylene blue,
respectively. After counting cells were centrifuged at 500×g for 5 minutes, the supernatant
was discarded, and the pellet was cryopreserved in Bambanker Freezing Media for storage
in liquid nitrogen until use.

To detect the EBV transcript, a custom EBV-specific primer was added to the cell
suspension immediately prior to loading onto the Chromium GEM-X Single Cell 5' v3 Gene
Expression platform (10x Genomics). The primer (sequence: 5′-AAG CAG TGG TAT CAA
CGC AGA GTA CAA AAC ATG CGG ACC ACC AGC-3′; 10 µM stock, 1 µL added per
sample) was synthesized by Integrated DNA Technologies. Libraries were sequenced on an
Illumina NovaSeqXP.

Single-cell RNAseq analysis

Sequenced reads were processed using Cell Ranger (v8.0.1) with pre-built reference refdata-gex-GRCh38-2024-A and refdata-cellranger-vdj-GRCh38-alts-ensembl-7.1.0 downloaded at 10x Genomics's Website. EBV transcripts were detected by VIRTUS3. For the pooled samples, donor assignment was performed using the Vireo pipeline[107] in Demuxafy.[108] For each sample, cell barcodes and the aligned BAM file generated by Cell Ranger were used as input to generate pileups of exonic SNPs. SNP pileup was performed using cellsnp-lite with the 1000 Genomes Project–derived genotype reference panel (GRCh38; MAF>0.01), applying filters of minimum allele count (minCOUNT≥20) and minor allele frequency (minMAF≥0.1). To restrict genotyping to the relevant donors, we subset the donor VCF to the SNPs detected in the sample-level pileup using bcftools. Vireo was run with an expected donor number of 8 and enabled ambient RNA modeling (--callAmbientRNAs). The downstream single-cell analysis was performed using scanpy 1.10.2.[109] The embedding and cluster assignment was performed using screfmapping pipeline with pre-defined B cell reference.[6] Briefly, we performed label transfer using CellTypist[110] with the model Immune_All_Low. B cell population was extracted based on the predicted cluster. Label transfer and embedding was performed by symphonypy with pre-defined B cell reference (the dataset will be published on Figshare).[111] BCR were analyzed using airrflow and scirpy.[112,113] DEG analysis was performed using Nebula[114], and gene set enrichment analysis was performed using ClusterProfiler.[115] For tonsil data analysis, we used Azimuth[116] with the tonsil reference dataset.[117]

BCR analysis

B-cell receptor analyses were performed using an integrated dataset containing GEX and BCR information. The analysis was restricted to cells from donors with at least one EBV-positive cell. EBV-positive cells were defined as those with EBV gene counts>0. BCR repertoire features, including SHM, were obtained using airrflow.[112] BCR clones were redefined separately for each donor using productive IGH contigs and scoper,[118] following the distToNearest, findThreshold, and hierarchicalClones workflow. SHM frequency and clonal expansion were evaluated within each cluster_L2 using models adjusted for donor.

Figure legends

Figure 1 EBV DNA GWAS reveals genetic architecture of EBV regulation

(A) EBV DNA positivity across predicted ancestors, gender, and age in blood (left) and saliva (right). AFR, African ancestry; AMR, Latino/admixed American ancestry; EAS, East Asian ancestry; EUR, European ancestry; SAS, South Asian ancestry (B) Distribution of EBV DNA fitted with Generalized Pareto distribution (GPD). Left: Simulated examples of GPD probability density functions illustrating the effect of the shape parameter ξ on the tail behavior: finite tail (ξ < 0), exponential tail (ξ = 0), and heavy tail (ξ > 0). Middle and Right: Histograms of normalized EBV DNA reads in blood (middle) and saliva (right). Orange curves represent GPD fits above the 95th percentile threshold (red dashed line). Estimated ξ values are shown for each sample type. (C) Manhattan plots showing genome-wide association statistics of EBV DNA presence. The y-axis shows $-\log_{10}P$ of each variant, and lead SNPs and annotated genes were highlighted. Heatmap shows the genes previously reported in MS,[2,4,119] SLE,[120] and RA[121] GWAS. The dashed line indicates a genome-wide significant level ($p=5.0\times10^{-8}$). Symbols indicate effect direction relative to the EBV GWAS (+ concordant, – discordant). Directional symbols are displayed only for loci reaching $P<5\times10^{-5}$ in the respective MS/SLE/RA GWAS, while nonsignificant or unavailable associations are shown as blank cells. Genes not reported in the GWASs with $P<5\times10^{-5}$ in the most significant loci of EBV DNA positivity GWAS were highlighted in light blue. Details are also available in Table S4. (D) Overlap of genes highlighted in MS onset GWAS,[2] MS severity GWAS[4] and EBV positivity GWAS. Statistical significance was evaluated using a two-tailed Fisher's exact test on a 2×2 contingency table, with all protein-coding genes (Gencode v47) used as the background (C and D). (E) EBV DNA positivity measured by qPCR across categories of the EBV DNA positivity PRS in an independent Yale cohort of European-ancestry individuals without MS (N = 94; 3 EBV DNA+ cases). (F) Schematic overview of the experimental design. JY cells, an EBV-positive B-cell line, were subjected to siRNA-mediated knockdown of host genes prioritized from the EBV DNA GWAS, and EBV transcripts were quantified by qPCR. (G) Heatmap showing changes in EBV transcript levels after knockdown of the indicated host genes at 24, 48, and 72 hours. Columns represent latent-associated (EBNA1, EBNA2, LMP1, LMP2) and lytic-associated (BZLF1, BMRF1, BLLF1) EBV transcripts. Color indicates fold change in transcript expression, with red indicating increased expression and blue indicating decreased expression. Asterisks indicate statistically significant changes tested by the Welch two-sample t-test. * : p < 0.05, ** : p < 0.01, *** : p < 0.001

Figure 2 Association of HLA alleles and amino acid variants with EBV DNA positivity and viral load.

(A) Locus plot of rs27300 in EBV Positivity GWAS. (B) eQTL plot of rs27300 in *ERAP2* and *LNPEP* in EBV-transformed lymphocytes. The eQTL data was downloaded from GTEx Portal.[122] (C) Associations between HLA alleles and EBV DNA positivity. The size of each point corresponds to the allele frequency, and the top associated alleles are labeled. The alleles highlighted by conditioning were also shown. HLA association analysis using All of Us European participants was performed by imputing classical HLA alleles with SNP2HLA. (D) Amino acid residue associated with EBV DNA positivity/viral load in HLA-A*02:01 (top) and HLA-DRB1*04:04 (bottom). The structures were downloaded from the PDB (3MRF for HLA-A*02:01 and 7nzf for HLA-DRB1*04:04).

Figure 3 Tissue- and cell-type–specific heritability enrichment for EBV positivity and viral load.

(A) UMAP visualization of PBMC single-cell RNA-seq data from EBV-positive and control individuals (DRA017005),[55] showing major immune cell clusters. (B) Cells with detected EBV transcripts identified by VIRTUS3 (blue) overlaid on the UMAP plot. (C) Comparison of the number of EBV-positive cells detected by VIRTUS3 versus Cell Ranger across samples. (D) Distribution of predicted cell types among EBV-positive cells, highlighting enrichment in plasmablasts and memory B cells. (E) Polygenic scores derived from the EBV DNA positivity GWAS in B memory and plasmablast populations. The Mann-Whitney U test was applied. (F) Region-level enrichment of EBV DNA positivity polygenic signals in tonsils[117] estimated by scDRS-spatial. Heatmap colors depict the proportion of significant cells (*FDR*<0.2) evaluated using scDRS[54] Squares denote significant disease associations (*FDR*<0.05). (g and h) Spatial transcriptomic map of human tonsil tissue showing annotated microanatomical regions and EBV DNA positivity polygenic scores across the same tissue section.

Figure 4 EBV DNA positivity is more frequent in patients with MS

(A) Frequency of EBV DNA+ in MS and non MS individuals in Yale cohort. (B) Scheimatic view of MS EBV DNA meta-analysis. (C) Forest plot showing OR and 95 percent confidence intervals for EBV DNA positivity comparing patients with multiple sclerosis (MS) and non-MS controls across published studies and our cohort. Squares indicate study-specific ORs with sizes proportional to study weights, and horizontal lines represent 95 percent CIs. The diamonds indicate the pooled effect estimates under fixed-effect and random-effects models. Quantification of heterogeneity: τ^2=0.0169, τ=0.1301, I^2=9.8 percent [0.0 percent; 49.4 percent], H=1.05 [1.00; 1.41]. A funnel plot is shown in Fig. S12.

Figure 5 Single-cell EBV detection from people with MS and healthy individuals

(A) Schematic view of scRNAseq experiments. (B and C) UMAP embedding of B-cell subsets from PBMCs (B) and EBV–positive cells (C). (D) Relationship between EBV copies per mL (qPCR) and the percentage of EBV$^+$ B cells, stratified by disease status (MS vs non-MS). The shaded region denotes a 95 percent confidence interval. Spearman's *rho* and *p-value* are shown in the figure. (E) Heatmap of viral transcript detection across B-cell subsets, displaying the number of cells expressing canonical EBV latent and lytic transcripts and aggregated EBV gene expression. (F) Representative clonal trees including EBV–positive cells. (G) Clonal network representations of clones containing EBV–positive cells and clones lacking EBV–positive cells. Node size indicates the number of cells in each cluster, and edge width indicates inter-cluster BCR repertoire similarity, defined as 1 - Jensen-Shannon divergence. Only the top 20% of edges by similarity are shown among clones with n >= 2 cells. Representative differential edges are marked by arrow heads.

Figure 6 Gene program changes in EBV-positive cells

(A) Gene Ontology (GO) enrichment analysis comparing EBV–positive versus EBV–negative cells for each B cell population. Dot size represents gene ratio, and color indicates adjusted *p*-value. (B) Dot plot showing expression level and $\log_2$ fold change of cytokines, chemokine receptors, and immunomodulatory molecules differentially expressed in EBV–positive cells. Differentially expressed genes are highlighted in bold circles. (C) scDRS-based polygenic score enrichment for EBV DNA positivity (left) and MS onset genes (right) across B-cell subsets, comparing EBV–positive and EBV–negative cells. A statistical test was performed by the Mann-Whitney U test. * : $p_{adj} < 0.05$, ** : $p_{adj} < 0.01$, *** : $p_{adj} < 0.001$. (D) Volcano plot of differentially expressed genes in EBV–positive versus EBV–negative switched memory B cells. Genes highlighted in the EBV and MS GWAS are annotated. (E) Schematic view of genetic EBV susceptibility in EBV-infected memory B cells and suggested T cell involvement. Genes in bold font are genes highlighted in EBV DNA GWAS.

Figure S1 Study design of cross-ancestry meta-analysis of EBV DNA GWAS.

Figure S2 Phenome-wide association study (PheWAS) of DNA EBV viral load in
European participants from the All of Us cohort.

(A) Forest plots showing odds ratios (points) and 95% confidence intervals (horizontal lines)
from logistic regression of EBV DNA positivity for blood samples (left) and saliva samples
(right). The age effect represents the change per 10-year increase. European ancestry and
male sex were used as references. The dashed line indicates *Odds ratio (OR)*=1. (B and C)
Phenome-wide association study (PheWAS) of EBV DNA positivity (B) and EBV DNA load
(C) in European participants from the All of Us cohort. Each point represents a clinical
phenotype, colored by disease category. The x-axis denotes phenotype groups and the y-
axis shows the $-log_{10}$*(FDR-adjusted P value)*. The dashed line indicates the FDR threshold
of 0.05. Details are available in Supplementary Tables 1 and 2.

Figure S3 QC plots and annotation of GWAS hits.

(A) Manhattan plots showing genome-wide association statistics of EBV DNA load.
log_{10}(Normalized EBV read) The y-axis shows $-log_{10}P$ of each variant, and lead SNPs and
annotated genes were highlighted. The dashed line indicates a genome-wide significant
level (p=5.0x10-8). Details are also available in Supplementary Table 4. (B) QQ plot of
GWAS for EBV DNA positivity (left) and EBV DNA load (right).

Figure S4 Supportive data for GWAS.

(A) Overlap of genes highlighted in MS onset GWAS, MS severity GWAS, and EBV load
GWAS. Statistical significance was assessed using a two-tailed Fisher's exact test. (B and
C) Locusplot of rs7726159 (*TERT2*) and rs2814778 (*ACKR1*, located near *IFI16*) in EBV
Positivity GWAS (D) Partitioned heritability enrichment in various genomic categories
calculated by S-LDSC. EBV DNA positivity (left) and EBV DNA load (right). (E) Gene
ontology biological process pathways enriched in GWAS of EBV DNA positivity (left) and
EBV DNA Load (right). Each dot represents a pathway, and the size indicates whether the
enrichment passed the FDR < 0.2 threshold.

Figure S5 Mendelian randomization and polygenic risk.

(A) Forest plots of Mendelian randomization (MR) estimates assessing the causal effect of
genetically predicted EBV DNA positivity on autoimmune diseases (multiple sclerosis [MS],
rheumatoid arthritis [RA], and systemic lupus erythematosus [SLE]) and stroke (negative
control). Three instrument sets were analyzed: whole genome, MHC-only, and genome
without the MHC region. Points represent odds ratios; horizontal lines indicate 95%
confidence intervals. The dashed vertical line indicates the null effect (OR = 1). (B) MS
prevalence across EBV DNA positivity PRS categories in the UK Biobank European-

ancestry cohort (N = 487,181; 2,423 MS cases). (C) EBV DNA positivity measured by qPCR
across categories of the EBV DNA positivity PRS in an independent Yale cohort of
European-ancestry individuals without MS (N = 94; 3 EBV DNA+ cases). For panels B and C,
PRSs were constructed using PRScs with All of Us European-ancestry GWAS (B) or the
European-ancestry meta-analysis GWAS (C) for three variant sets: whole genome, MHC-
only, and non-MHC. Individuals were stratified into bottom 10%, middle 80%, and top 10% of
each PRS distribution. Percentages indicate the proportion of MS cases (B) or EBV DNA-
positive individuals (C) or within each category.

Figure S6 HLA association with EBV DNA load.
(A) Locus plot of rs27300 in EBV viral load GWAS. (B) Associations between HLA alleles
and EBV DNA load. The size of each point corresponds to the allele frequency, and the top
associated alleles are labeled. The alleles highlighted by conditioning were also shown. (C)
Sequence logos of ERAP2-dependent (top) and ERAP2-sensitive (bottom) peptides derived
from pan–MHC class I (W6/32) immunopeptidomics in EBV LCLs.[52] Logos represent
position-specific enrichment (log2 scale) relative to background amino acid frequencies
across all peptides. Positions are indexed from the peptide N-terminus. (D) Distribution of
W6/32-derived ERAP2 scores stratified by HLA locus. Top panels show histograms for HLA-
A, HLA-B, and HLA-C. Blue indicates human class I ligands from IEDB[103]; orange indicates
EBV-derived class I peptides.[35] Vertical lines denote a score of 0. Bottom panels list the top
five EBV peptides for each locus, with corresponding source gene and ERAP2 score.

Figure S7 Conditioning of HLA allele and amino acids association with EBV
DNA Positivity.
Association results for classical HLA alleles across loci (left) and amino acids (right) shown
as $-\log_{10}$(P values). The most strongly associated alleles in each conditioning round are
labeled. HLA amino acid association results for EBV DNA positivity across iterative
conditional analyses (Rounds 0–5).

Figure S8 Conditioning of HLA allele and amino acids association with EBV
DNA load.
Association results for classical HLA alleles across loci (left) and amino acids (right) shown
as $-\log_{10}$(P values). The most strongly associated alleles in each conditioning round are
labeled. HLA amino acid association results for EBV DNA load across iterative conditional
analyses (Rounds 0–5).

Figure S9 Biological interpretation of GWAS results.
(A) Partitioned heritability was estimated using LD score regression for EBV DNA Positivity
(left) and EBV DNA load (right). Each dot represents a tissue or cell-type annotation, and the

size indicates whether the enrichment passed the *FDR*<0.2 threshold. (A) Proportion of scDRS-significant cells (*FDR*<0.2) across immune cell types for EBV DNA positivity and viral load. (B) Polygenic scores derived from the EBV load GWAS in B memory and plasmablast populations. The Mann-Whitney U test was applied. (C and D) Enrichment in tissues (C) and anatomical regions in tonsils (D) of EBV polygenic signals estimated by scDRS-spatial. Heatmap colors depict the proportion of significant cells (*FDR*<0.2) evaluated using scDRS. Squares denote significant disease associations (*FDR*<0.05), and cross symbols denote significant heterogeneity in association (*FDR*<0.05).

Figure S10 Schematic overview of the VIRTUS3 algorithm for EBV transcript detection in 10x single-cell RNA-seq data.

In conventional Cell Ranger-based pipelines using a combined human and EBV reference, overlapping reads can be discarded and reads with sequence similarity to human transcripts can be misaligned, reducing sensitivity for the compact EBV genome. VIRTUS3 addresses this problem through a two-step strategy: reads are first aligned to the human reference with Cell Ranger to generate the human gene-count matrix, and unmapped reads are subsequently recovered and re-analyzed against the EBV transcriptome with Alevin.[95] This design enables stringent filtering of human-like reads and appropriate handling of multi-mapped viral reads.

Figure S11 Funnel plot assessing publication bias in studies comparing EBV DNA positivity between MS and controls.

Each point represents an individual study included in the meta-analysis. The vertical dashed line indicates the pooled odds ratio under the common-effect model (*OR*=1.77). The dashed diagonal lines denote the 95 percent confidence limits of the expected distribution in the absence of publication bias.

Figure S12 EBV profiling of tonsils from MS and nonMS individuals

(A and B) UMAP plot showing predicted clusters (A) and detected EBV–positive cells (B).

Figure S13 EBV profiling of blood B cells from MS and nonMS individuals

(A) Percentage of EBV–positive cells across B cell populations per samples. Rows indicate each donor. The heatmap in orange shows qPCR based copy number of EBV DNA in blood. (B) Forest plot showing the association of isotype with EBV DNA positivity. Clusters were treated as a covariate to extract global isotype preference. IGHE, IGHG3, IGHG4 were removed from the plot because no EBV–positive cells were detected. (C) Somatic hypermutation frequency distribution across clusters between EBV–positive and EBV-negative cells.

Figure S14 EBV transcriptional states and B-cell receptor features of EBV-positive B cells across donors.

(A) Donor-level overview of EBV-positive B cells. Rows represent individual donors. Left annotation bars indicate disease category and whole-blood EBV DNA load measured by qPCR targeting BamH1W. The middle heatmap shows the fraction of EBV-positive cells within each donor-by-cluster_L2 combination. The right heatmap shows the distribution of EBV transcriptional states among EBV-positive cells from each donor, including Latent, BARF0/A73, Context dependent, IE, Early, and Late states. (B) Effect of EBV positivity on somatic hypermutation (SHM) frequency across B-cell subsets. Points indicate effect estimates, and horizontal lines indicate 95% confidence intervals. (C) Association between EBV positivity and immunoglobulin isotype usage. Points indicate odds ratios for isotype choice in EBV-positive cells, and horizontal lines indicate 95% confidence intervals. (D) Enrichment of clonal expansion in EBV-positive cells across B-cell subsets. Points indicate odds ratios for membership in expanded clones (clone size ≥2) in EBV-positive cells, and horizontal lines indicate 95% confidence intervals. Asterisks denote statistically significant associations.

Supplementary Tables

Supplementary Table 1 PheWAS of Whole-Blood EBV Positivity in AoU European Participants

Supplementary Table 2 PheWAS of Whole-Blood EBV DNA Load in AoU European Participants

Supplementary Table 3 Number individuals and λ_{GC} of individual GWAS

Supplementary Table 4 Lead SNPs of cross-ancestry meta-analysis

Supplementary Table 5 Statistics of EBV Positivity GWAS top hits in all single GWAS

Supplementary Table 6 Statistics of EBV viral load GWAS top hits in all single GWAS

Supplementary Table 7 MAGMA Gene-Set Associations with EBV DNA Positivity

Supplementary Table 8 MAGMA Gene-Set Associations with EBV DNA Load

Supplementary Table 9 Mendelian Randomization analysis with EBV and autoimmune GWAS

Supplementary Table 10 Polygenic Risk Score analysis with EBV GWAS and autoimmune diseases

Supplementary Table 11 Polygenic Risk Score analysis with EBV GWAS and EBV DNA positivity in Yale cohort.

Supplementary Table 12 HLA allele associated with EBV Positivity

Supplementary Table 13 HLA allele associated with EBV DNA Load

Supplementary Table 14 HLA amino acids associated with EBV Positivity

Supplementary Table 15 HLA amino acids associated with EBV DNA Load

Supplementary Table 16 meta analysis of EBV DNA Positivity

1309 **Supplementary Table 17 Sample information for scRNAseq**

1310 **Supplementary Table 18 Differentially expressed genes in EBV–positive cells**

1311 **Supplementary Table 19 pathway enriched in EBV–positive cells**

1312 **Supplementary Table 20 Reagents and primers used for the experiments**

1313

Reference

1. Hafler, D.A., and Weiner, H.L. (1989). MS: a CNS and systematic autoimmune disease. Immunol. Today *10*, 104–107.

2. Patsopoulos, N.A., Baranzini, S.E., Santaniello, A., Shoostari, P., Cotsapas, C., Wong, G., Beecham, A.H., James, T., Replogle, J., Vlachos, I.S., et al. (2019). Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science *365*, eaav7188.

3. International Multiple Sclerosis Genetics Consortium, Hafler, D.A., Compston, A., Sawcer, S., Lander, E.S., Daly, M.J., De Jager, P.L., de Bakker, P.I.W., Gabriel, S.B., Mirel, D.B., et al. (2007). Risk alleles for multiple sclerosis identified by a genomewide study. N. Engl. J. Med. *357*, 851–862.

4. International Multiple Sclerosis Genetics Consortium, and MultipleMS Consortium (2023). Locus for severity implicates CNS resilience in progression of multiple sclerosis. Nature *619*, 323–331.

5. Farh, K.K.-H., Marson, A., Zhu, J., Kleinewietfeld, M., Housley, W.J., Beik, S., Shoresh, N., Whitton, H., Ryan, R.J.H., Shishkin, A.A., et al. (2015). Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature *518*, 337–343.

6. Yasumizu, Y., Takeuchi, D., Morimoto, R., Takeshima, Y., Okuno, T., Kinoshita, M., Morita, T., Kato, Y., Wang, M., Motooka, D., et al. (2024). Single-cell transcriptome landscape of circulating CD4+ T cell populations in autoimmune diseases. Cell Genom *4*, 100473.

7. Pappalardo, J.L., Zhang, L., Pecsok, M.K., Perlman, K., Zografou, C., Raddassi, K., Abulaban, A., Krishnaswamy, S., Antel, J., van Dijk, D., et al. (2020). Transcriptomic and clonal characterization of T cells in the human central nervous system. Sci. Immunol. *5*. https://doi.org/10.1126/sciimmunol.abb8786.

8. Cao, Y., Goods, B.A., Raddassi, K., Nepom, G.T., Kwok, W.W., Love, J.C., and Hafler, D.A. (2015). Functional inflammatory profiles distinguish myelin-reactive T cells from patients with multiple sclerosis. Sci. Transl. Med. *7*, 287ra74.

9. Sumida, T.S., Lincoln, M.R., He, L., Park, Y., Ota, M., Oguchi, A., Son, R., Yi, A., Stillwell, H.A., Leissa, G.A., et al. (2024). An autoimmune transcriptional circuit drives FOXP3+ regulatory T cell dysfunction. Sci. Transl. Med. *16*, eadp1720.

10. Viglietta, V., Baecher-Allan, C., Weiner, H.L., and Hafler, D.A. (2004). Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. *199*, 971–979.

11. Schafflick, D., Xu, C.A., Hartlehnert, M., Cole, M., Schulte-Mecklenbeck, A., Lautwein,

T., Wolbert, J., Heming, M., Meuth, S.G., Kuhlmann, T., et al. (2020). Integrated single
cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat.
Commun. *11*, 247.

12. Bjornevik, K., Cortese, M., Healy, B.C., Kuhle, J., Mina, M.J., Leng, Y., Elledge, S.J.,
Niebuhr, D.W., Scher, A.I., Munger, K.L., et al. (2022). Longitudinal analysis reveals
high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science *375*,
296–301.

13. Soldan, S.S., Su, C., Monaco, M.C., Yoon, L., Kannan, T., Zankharia, U., Patel, R.J.,
Dheekollu, J., Vladimirova, O., Dowling, J.W., et al. (2024). Multiple sclerosis patient-
derived spontaneous B cells have distinct EBV and host gene expression profiles in
active disease. Nat. Microbiol. *9*, 1540–1554.

14. Agostini, S., Mancuso, R., Guerini, F.R., D'Alfonso, S., Agliardi, C., Hernis, A.,
Zanzottera, M., Barizzone, N., Leone, M.A., Caputo, D., et al. (2018). HLA alleles
modulate EBV viral load in multiple sclerosis. J. Transl. Med. *16*, 80.

15. Bray, P.F., Bloomer, L.C., Salmon, V.C., Bagley, M.H., and Larsen, P.D. (1983).
Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis.
Arch. Neurol. *40*, 406–408.

16. Schneider-Hohendorf, T., Wünsch, C., Falk, S., Raposo, C., Rubelt, F., Mirebrahim, H.,
Asgharian, H., Schlecht, U., Mattox, D., Zhou, W., et al. (2025). Broader anti-EBV TCR
repertoire in multiple sclerosis: disease specificity and treatment modulation. Brain *148*,
933–940.

17. Schneider-Hohendorf, T., Gerdes, L.A., Pignolet, B., Gittelman, R., Ostkamp, P., Rubelt,
F., Raposo, C., Tackenberg, B., Riepenhausen, M., Janoschka, C., et al. (2022).
Broader Epstein-Barr virus-specific T cell receptor repertoire in patients with multiple
sclerosis. J. Exp. Med. *219*. https://doi.org/10.1084/jem.20220650.

18. Lanz, T.V., Brewer, R.C., Ho, P.P., Moon, J.-S., Jude, K.M., Fernandez, D., Fernandes,
R.A., Gomez, A.M., Nadj, G.-S., Bartley, C.M., et al. (2022). Clonally expanded B cells
in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature *603*, 321–327.

19. Wucherpfennig, K.W., and Strominger, J.L. (1995). Molecular mimicry in T cell-mediated
autoimmunity: viral peptides activate human T cell clones specific for myelin basic
protein. Cell *80*, 695–705.

20. Thomas, O.G., Rykaczewska, U., Galešić, M., van der Burgt, R.T.M., Hallén, N., Ferro,
F., Bronge, M., Marti, Z., Li, Y., Riqué, A.H., et al. (2026). Anoctamin-2-specific T cells
link Epstein-Barr virus to multiple sclerosis. Cell *0*.
https://doi.org/10.1016/j.cell.2025.12.032.

21. Küppers, R. (2003). B cells under influence: transformation of B cells by Epstein-Barr

virus. Nat. Rev. Immunol. *3*, 801–812.

22. Wei, J., Moon, J., Yasumizu, Y., Zhang, L., Radassi, K., Buitrago-Pocasangre, N.,
Deerhake, M.E., Strauli, N., Chen, C.-W., Herman, A., et al. (2025). Transcriptomic
profiling after B cell depletion reveals central and peripheral immune cell changes in
multiple sclerosis. J. Clin. Invest. *135*. https://doi.org/10.1172/JCI182790.

23. Damania, B., Kenney, S.C., and Raab-Traub, N. (2022). Epstein-Barr virus: Biology and
clinical disease. Cell *185*, 3652–3670.

24. Xu, Y., Hiyoshi, A., Smith, K.A., Piehl, F., Olsson, T., Fall, K., and Montgomery, S.
(2021). Association of infectious mononucleosis in childhood and adolescence with risk
for a subsequent multiple sclerosis diagnosis among siblings. JAMA Netw. Open *4*,
e2124932.

25. Hwang, A.E., Hamilton, A.S., Cockburn, M.G., Ambinder, R., Zadnick, J., Brown, E.E.,
Mack, T.M., and Cozen, W. (2012). Evidence of genetic susceptibility to infectious
mononucleosis: a twin study. Epidemiol. Infect. *140*, 2089–2095.

26. Larsen, P.D., Bloomer, L.C., and Bray, P.F. (1985). Epstein-Barr nuclear antigen and
viral capsid antigen antibody titers in multiple sclerosis. Neurology *35*, 435–438.

27. Li, Z.-X., Zeng, S., Wu, H.-X., and Zhou, Y. (2019). The risk of systemic lupus
erythematosus associated with Epstein-Barr virus infection: a systematic review and
meta-analysis. Clin. Exp. Med. *19*, 23–36.

28. Chan, K.C.A., Woo, J.K.S., King, A., Zee, B.C.Y., Lam, W.K.J., Chan, S.L., Chu, S.W.I.,
Mak, C., Tse, I.O.L., Leung, S.Y.M., et al. (2017). Analysis of plasma Epstein-Barr virus
DNA to screen for nasopharyngeal cancer. N. Engl. J. Med. *377*, 513–522.

29. McLaren, P.J., Coulonges, C., Bartha, I., Lenz, T.L., Deutsch, A.J., Bashirova, A.,
Buchbinder, S., Carrington, M.N., Cossarizza, A., Dalmau, J., et al. (2015).
Polymorphisms of large effect explain the majority of the host genetic contribution to
variation of HIV-1 virus load. Proc. Natl. Acad. Sci. U. S. A. *112*, 14658–14663.

30. Yasumizu, Y., Hara, A., Sakaguchi, S., and Ohkura, N. (2021). VIRTUS: a pipeline for
comprehensive virus analysis from conventional RNA-seq data. Bioinformatics *37*,
1465–1467.

31. Kumata, R., Ito, J., Takahashi, K., Suzuki, T., and Sato, K. (2020). A tissue level atlas of
the healthy human virome. BMC Biol. *18*, 55.

32. Sasa, N., Kojima, S., Koide, R., Hasegawa, T., Namkoong, H., Hirota, T., Watanabe, R.,
Nakamura, Y., Oguro-Igashira, E., Ogawa, K., et al. (2025). Blood DNA virome
associates with autoimmune diseases and COVID-19. Nat. Genet. *57*, 65–79.

33. Kachuri, L., Francis, S.S., Morrison, M.L., Wendt, G.A., Bossé, Y., Cavazos, T.B.,
Rashkin, S.R., Ziv, E., and Witte, J.S. (2020). The landscape of host genetic factors

involved in immune response to common viral infections. Genome Med. *12*, 93.

34. Guo, J., Huang, X., Zhang, C., Huang, P., Li, Y., Wen, F., Wang, X., Yang, N., Xu, M., Bi, Y., et al. (2022). The blood virome of 10,585 individuals from the ChinaMAP. Cell Discov. *8*, 113.

35. Nyeo, S.S., Cumming, E.M., Burren, O.S., Pagadala, M.S., Gutierrez, J.C., Ali, T.A., Kida, L.C., Chen, Y., Chu, H., Hu, F., et al. (2026). Population-scale sequencing resolves determinants of persistent EBV DNA. Nature *650*, 664–672.

36. Schmidt, A., Alawathurage, T.M., David, F.S., Ogawa, Y., Frach, L., Richter, S., Schaefer, M., Mathey, C.M., Henne, S.K., Japan COVID-19 Task Force, et al. (2026). Host control of persistent Epstein-Barr virus infection. Nature, 1–5.

37. All of Us Research Program Genomics Investigators (2024). Genomic data in the All of Us Research Program. Nature *627*, 340–346.

38. UK Biobank Whole-Genome Sequencing Consortium (2025). Whole-genome sequencing of 490,640 UK Biobank participants. Nature *645*, 692–701.

39. McManus, T.E., Marley, A.-M., Baxter, N., Christie, S.N., Elborn, J.S., O'Neill, H.J., Coyle, P.V., and Kidney, J.C. (2008). High levels of Epstein-Barr virus in COPD. Eur. Respir. J. *31*, 1221–1226.

40. Mbatchou, J., Barnard, L., Backman, J., Marcketta, A., Kosmicki, J.A., Ziyatdinov, A., Benner, C., O'Dushlaine, C., Barber, M., Boutkov, B., et al. (2021). Computationally efficient whole-genome regression for quantitative and binary traits. Nat. Genet. *53*, 1097–1103.

41. Willer, C.J., Li, Y., and Abecasis, G.R. (2010). METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics *26*, 2190–2191.

42. Mägi, R., Horikoshi, M., Sofer, T., Mahajan, A., Kitajima, H., Franceschini, N., McCarthy, M.I., COGENT-Kidney Consortium, T2D-GENES Consortium, and Morris, A.P. (2017). Trans-ethnic meta-regression of genome-wide association studies accounting for ancestry increases power for discovery and improves fine-mapping resolution. Hum. Mol. Genet. *26*, 3639–3650.

43. Bulik-Sullivan, B.K., Loh, P.-R., Finucane, H.K., Ripke, S., Yang, J., Schizophrenia Working Group of the Psychiatric Genomics Consortium, Patterson, N., Daly, M.J., Price, A.L., and Neale, B.M. (2015). LD Score regression distinguishes confounding from polygenicity in genome-wide association studies. Nat. Genet. *47*, 291–295.

44. Wen, S., Kuri-Morales, P., Hu, F., Nag, A., Tachmazidou, I., Deevi, S.V.V., Taiy, H., Smith, K.R., Loesch, D.P., Burren, O.S., et al. (2025). Comparative analysis of the Mexico City Prospective Study and the UK Biobank identifies ancestry-specific effects on clonal hematopoiesis. Nat. Genet. *57*, 572–582.

45. Dolcetti, R., Giunco, S., Dal Col, J., Celeghin, A., Mastorci, K., and De Rossi, A. (2014). Epstein-Barr virus and telomerase: from cell immortalization to therapy. Infect. Agent. Cancer *9*, 8.

46. Witt, K.C., Dziulko, A., An, J., Pekovic, F., Cheng, A.X., Liu, G.Y., Lee, O.V., Turner, D.J., Lari, A., Gaidt, M.M., et al. (2025). SP140-RESIST pathway regulates interferon mRNA stability and antiviral immunity. Nature *643*, 1372–1380.

47. Amatullah, H., Fraschilla, I., Digumarthi, S., Huang, J., Adiliaghdam, F., Bonilla, G., Wong, L.P., Rivard, M.-E., Beauchamp, C., Mercier, V., et al. (2022). Epigenetic reader SP140 loss of function drives Crohn's disease due to uncontrolled macrophage topoisomerases. Cell *185*, 3232-3247.e18.

48. Sumida, T.S., Dulberg, S., Schupp, J.C., Lincoln, M.R., Stillwell, H.A., Axisa, P.-P., Comi, M., Unterman, A., Kaminski, N., Madi, A., et al. (2022). Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat. Immunol. *23*, 632–642.

49. Finucane, H.K., Bulik-Sullivan, B., Gusev, A., Trynka, G., Reshef, Y., Loh, P.-R., Anttila, V., Xu, H., Zang, C., Farh, K., et al. (2015). Partitioning heritability by functional annotation using genome-wide association summary statistics. Nat. Genet. *47*, 1228–1235.

50. Ge, T., Chen, C.-Y., Ni, Y., Feng, Y.-C.A., and Smoller, J.W. (2019). Polygenic prediction via Bayesian regression and continuous shrinkage priors. Nat. Commun. *10*, 1776.

51. Jia, X., Han, B., Onengut-Gumuscu, S., Chen, W.-M., Concannon, P.J., Rich, S.S., Raychaudhuri, S., and de Bakker, P.I.W. (2013). Imputing amino acid polymorphisms in human leukocyte antigens. PLoS One *8*, e64683.

52. Venema, W.J., Hiddingh, S., de Boer, J.H., Claas, F.H.J., Mulder, A., den Hollander, A.I., Stratikos, E., Sarkizova, S., van der Veken, L.T., Janssen, G.M.C., et al. (2021). ERAP2 increases the abundance of a peptide submotif highly selective for the birdshot Uveitis-associated HLA-A29. Front. Immunol. *12*, 634441.

53. Finucane, H.K., Reshef, Y.A., Anttila, V., Slowikowski, K., Gusev, A., Byrnes, A., Gazal, S., Loh, P.-R., Lareau, C., Shoresh, N., et al. (2018). Heritability enrichment of specifically expressed genes identifies disease-relevant tissues and cell types. Nat. Genet. *50*, 621–629.

54. Zhang, M.J., Hou, K., Dey, K.K., Sakaue, S., Jagadeesh, K.A., Weinand, K., Taychameekiatchai, A., Rao, P., Pisco, A.O., Zou, J., et al. (2022). Polygenic enrichment distinguishes disease associations of individual cells in single-cell RNA-seq data. Nat. Genet., 1–9.

55. Suzuki, T., Sato, Y., Okuno, Y., Torii, Y., Fukuda, Y., Haruta, K., Yamaguchi, M.,
Kawamura, Y., Hama, A., Narita, A., et al. (2024). Single-Cell Transcriptomic Analysis of
Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis. J. Clin. Immunol.
44, 103.

56. Cell Ranger's Gene Expression Algorithm 10x Genomics.
https://www.10xgenomics.com/support/software/cell-ranger/latest/algorithms-
overview/cr-gex-algorithm.

57. Yasumizu, Y., Kinoshita, M., Zhang, M.J., Motooka, D., Suzuki, K., Nojima, S., Koizumi,
N., Okuzaki, D., Funaki, S., Shintani, Y., et al. (2024). Spatial transcriptomics elucidates
medulla niche supporting germinal center response in myasthenia gravis-associated
thymoma. Cell Reports *43*. https://doi.org/10.1016/j.celrep.2024.114677.

58. Sorgato, C.C., Lins-E-Silva, M., Leão, J.C., Vasconcelos, L.R., Romão, T.P., Duarte,
A.L., and Gueiros, L.A. (2020). EBV and CMV viral load in rheumatoid arthritis and their
role in associated Sjögren's syndrome. J. Oral Pathol. Med. *49*, 693–700.

59. Bäckerholm, A., Tian, Y., Holmqvist, I., Xie, G., Vracar, D., Abrahamsson, S., Guibentif,
C., and Tang, K.-W. (2022). Detection of latent Epstein-Barr virus gene expression in
single-cell sequencing of peripheral blood mononuclear cells. Microbiology.

60. Younis, S., Moutusy, S.I., Rasouli, S., Jahanbani, S., Pandit, M., Wu, X., Acharya, S.,
Sharpe, O., Wijeratne, T.U., Harris, M.L., et al. (2025). Epstein-Barr virus reprograms
autoreactive B cells as antigen-presenting cells in systemic lupus erythematosus. Sci.
Transl. Med. *17*, eady0210.

61. Fournier, B., Boutboul, D., Bruneau, J., Miot, C., Boulanger, C., Malphettes, M., Pellier,
I., Dunogué, B., Terrier, B., Suarez, F., et al. (2020). Rapid identification and
characterization of infected cells in blood during chronic active Epstein-Barr virus
infection. J. Exp. Med. *217*. https://doi.org/10.1084/jem.20192262.

62. Läderach, F., Piteros, I., Fennell, É., Bremer, E., Last, M., Schmid, S., Rieble, L.,
Campbell, C., Ludwig-Portugall, I., Bornemann, L., et al. (2025). EBV induces CNS
homing of B cells attracting inflammatory T cells. Nature *646*, 171–179.

63. Nyeo, S.S., Cumming, E.M., Burren, O.S., Pagadala, M.S., Gutierrez, J.C., Ali, T.A.,
Kida, L.C., Chen, Y., Hu, F., Hollis, B., et al. (2025). Population-scale sequencing
resolves correlates and determinants of latent Epstein-Barr Virus infection. Genetics.

64. Montalban, X., Lebrun-Frénay, C., Oh, J., Arrambide, G., Moccia, M., Pia Amato, M.,
Amezcua, L., Banwell, B., Bar-Or, A., Barkhof, F., et al. (2025). Diagnosis of multiple
sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. *24*, 850–865.

65. Makhani, N., and Tremlett, H. (2021). The multiple sclerosis prodrome. Nat. Rev.
Neurol. *17*, 515–521.

66. Ford, J.L., and Stowe, R.P. (2013). Racial-ethnic differences in Epstein-Barr virus
antibody titers among U.S. children and adolescents. Ann. Epidemiol. *23*, 275–280.

67. Lee, J., Manon, V., and Chen, J. (2025). Structurally diverse viral inhibitors converge on
a shared mechanism to stall the antigen transporter TAP. Proc. Natl. Acad. Sci. U. S. A.
122, e2516676122.

68. Raychaudhuri, S., Sandor, C., Stahl, E.A., Freudenberg, J., Lee, H.-S., Jia, X.,
Alfredsson, L., Padyukov, L., Klareskog, L., Worthington, J., et al. (2012). Five amino
acids in three HLA proteins explain most of the association between MHC and
seropositive rheumatoid arthritis. Nat. Genet. *44*, 291–296.

69. Patsopoulos, N.A., Barcellos, L.F., Hintzen, R.Q., Schaefer, C., van Duijn, C.M., Noble,
J.A., Raj, T., IMSGC, ANZgene, Gourraud, P.-A., et al. (2013). Fine-mapping the
genetic association of the major histocompatibility complex in multiple sclerosis: HLA
and non-HLA effects. PLoS Genet. *9*, e1003926.

70. Mycko, M.P., Waldner, H., Anderson, D.E., Bourcier, K.D., Wucherpfennig, K.W.,
Kuchroo, V.K., and Hafler, D.A. (2004). Cross-reactive TCR responses to self antigens
presented by different MHC class II molecules. J. Immunol. *173*, 1689–1698.

71. Moutsianas, L., Jostins, L., Beecham, A.H., Dilthey, A.T., Xifara, D.K., Ban, M., Shah,
T.S., Patsopoulos, N.A., Alfredsson, L., Anderson, C.A., et al. (2015). Class II HLA
interactions modulate genetic risk for multiple sclerosis. Nat. Genet. *47*, 1107–1113.

72. Niens, M., Jarrett, R.F., Hepkema, B., Nolte, I.M., Diepstra, A., Platteel, M., Kouprie, N.,
Delury, C.P., Gallagher, A., Visser, L., et al. (2007). HLA-A*02 is associated with a
reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin
lymphoma. Blood *110*, 3310–3315.

73. Ishigaki, K., Lagattuta, K.A., Luo, Y., James, E.A., Buckner, J.H., and Raychaudhuri, S.
(2022). HLA autoimmune risk alleles restrict the hypervariable region of T cell receptors.
Nat. Genet. *54*, 393–402.

74. Raja, A., Reeves, E., Alasiri, A., de Ligt, A., Yermanos, A., de Boer, J.H., Ossewaarde-
van Norel, J., Mpakali, A., Stratikos, E., van Vugt, M., et al. (2026). ERAP2 protein
allotypes show functional diversity in MHC-I antigen presentation in the human
population.   medRxiv,   2026.01.22.26344601.
https://doi.org/10.64898/2026.01.22.26344601.

75. Schmidt, A., Alawathurage, T.M., Frach, L., Richter, S., David, F.S., Schaefer, M.,
Henne, S.K., Boztug, K., Proebstel, A.-K., Noethen, M.M., et al. (2025). Host control of
latent   Epstein-Barr   virus   infection.   medRxiv,   2025.07.19.25331823.
https://doi.org/10.1101/2025.07.19.25331823.

76. Lazarian, G., Yin, S., Ten Hacken, E., Sewastianik, T., Uduman, M., Font-Tello, A.,

Gohil, S.H., Li, S., Kim, E., Joyal, H., et al. (2021). A hotspot mutation in transcription
factor IKZF3 drives B cell neoplasia via transcriptional dysregulation. Cancer Cell *39*,
380-393.e8.

77. Devergne, O., Hatzivassiliou, E., Izumi, K.M., Kaye, K.M., Kleijnen, M.F., Kieff, E., and
Mosialos, G. (1996). Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr
virus LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB
activation. Mol. Cell. Biol. *16*, 7098–7108.

78. Cable, J.M., Wongwiwat, W., Grabowski, J.C., White, R.E., and Luftig, M.A. (2025).
Sp140L functions as a herpesvirus restriction factor suppressing viral transcription and
activating interferon-stimulated genes. Proc. Natl. Acad. Sci. U. S. A. *122*,
e2426339122.

79. Boisvert, F.M., Hendzel, M.J., and Bazett-Jones, D.P. (2000). Promyelocytic leukemia
(PML) nuclear bodies are protein structures that do not accumulate RNA. J. Cell Biol.
148, 283–292.

80. Xu, H., Li, X., Rousseau, B.A., Akinyemi, I.A., Frey, T.R., Zhou, K., Droske, L.E.,
Mitchell, J.A., McIntosh, M.T., and Bhaduri-McIntosh, S. (2022). IFI16 partners with
KAP1 to maintain Epstein-Barr virus latency. J. Virol. *96*, e0102822.

81. Harley, J.B., Chen, X., Pujato, M., Miller, D., Maddox, A., Forney, C., Magnusen, A.F.,
Lynch, A., Chetal, K., Yukawa, M., et al. (2018). Transcription factors operate across
disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. *50*, 699–707.

82. Deltombe, M., Stölting, A., Maggi, P., and van Pesch, V. (2025). FCRL5, a B-cell marker
with novel diagnostic and prognostic value for multiple sclerosis. Neurol. Neuroimmunol.
Neuroinflamm. *12*, e200485.

83. SoRelle, E.D., Haukenfrers, E., Horn, G.Q., Jain, V., Giarraputo, J., Abramson, K.,
Hocke, E., Cooney, L.A., Harris, K.M., Zamvil, S.S., et al. (5 2025). Early multiple
sclerosis activity associated with TBX21+CD21loCXCR3+ B cell expansion resembling
EBV-induced phenotypes. JCI Insight *10*. https://doi.org/10.1172/jci.insight.188543.

84. Pérez-Mazliah, D., Gardner, P.J., Schweighoffer, E., McLaughlin, S., Hosking, C.,
Tumwine, I., Davis, R.S., Potocnik, A.J., Tybulewicz, V.L., and Langhorne, J. (2018).
Plasmodium-specific atypical memory B cells are short-lived activated B cells. Elife *7*.
https://doi.org/10.7554/eLife.39800.

85. Kurosaki, T., Kometani, K., and Ise, W. (2015). Memory B cells. Nat. Rev. Immunol. *15*,
149–159.

86. Koch, M.A., Thomas, K.R., Perdue, N.R., Smigiel, K.S., Srivastava, S., and Campbell,
D.J. (2012). T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired
expression of IL-12 receptor β2. Immunity *37*, 501–510.

87. Knippenberg, S., Peelen, E., Smolders, J., Thewissen, M., Menheere, P., Cohen
Tervaert, J.W., Hupperts, R., and Damoiseaux, J. (2011). Reduction in IL-10 producing
B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg
ratio during a relapse but not in remission. J. Neuroimmunol. *239*, 80–86.

88. Li, B., Veturi, Y., Lucas, A., Bradford, Y., Verma, S.S., Verma, A., Park, J., Wei, W.-Q.,
Feng, Q., Namjou, B., et al. (2021). Multi-ancestry gene-trait connection landscape
using electronic health record (EHR) linked biobank data. bioRxiv.
https://doi.org/10.1101/2021.10.21.21265225.

89. He, Y., Koido, M., Shimmori, Y., and Kamatani, Y. (2023). GWASLab: a Python
package for processing and visualizing GWAS summary statistics.

90. McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P.,
and Cunningham, F. (2016). The Ensembl Variant Effect Predictor. Genome Biol. *17*,
122.

91. Ochoa, D., Hercules, A., Carmona, M., Suveges, D., Baker, J., Malangone, C., Lopez,
I., Miranda, A., Cruz-Castillo, C., Fumis, L., et al. (2023). The next-generation Open
Targets Platform: reimagined, redesigned, rebuilt. Nucleic Acids Res. *51*, D1353–
D1359.

92. Ota, M., Nagafuchi, Y., Hatano, H., Ishigaki, K., Terao, C., Takeshima, Y., Yanaoka, H.,
Kobayashi, S., Okubo, M., Shirai, H., et al. (2021). Dynamic landscape of immune cell-
specific gene regulation in immune-mediated diseases. Cell *184*, 3006-3021.e17.

93. de Leeuw, C.A., Mooij, J.M., Heskes, T., and Posthuma, D. (2015). MAGMA:
generalized gene-set analysis of GWAS data. PLoS Comput. Biol. *11*, e1004219.

94. Shuey, M.M., Stead, W.W., Aka, I., Barnado, A.L., Bastarache, J.A., Brokamp, E.,
Campbell, M., Carroll, R.J., Goldstein, J.A., Lewis, A., et al. (2023). Next-generation
phenotyping: introducing phecodeX for enhanced discovery research in medical
phenomics. Bioinformatics *39*. https://doi.org/10.1093/bioinformatics/btad655.

95. Srivastava, A., Malik, L., Smith, T., Sudbery, I., and Patro, R. (2019). Alevin efficiently
estimates accurate gene abundances from dscRNA-seq data. Genome Biol. *20*, 65.

96. van Dijk, D., Sharma, R., Nainys, J., Yim, K., Kathail, P., Carr, A.J., Burdziak, C., Moon,
K.R., Chaffer, C.L., Pattabiraman, D., et al. (2018). Recovering Gene Interactions from
Single-Cell Data Using Data Diffusion. Cell *174*, 716-729.e27.

97. Sakaue, S., Gurajala, S., Curtis, M., Luo, Y., Choi, W., Ishigaki, K., Kang, J.B., Rumker,
L., Deutsch, A.J., Schönherr, S., et al. (2023). Tutorial: a statistical genetics guide to
identifying HLA alleles driving complex disease. Nat. Protoc. *18*, 2625–2641.

98. Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., and Lee, J.J. (2015).
Second-generation PLINK: rising to the challenge of larger and richer datasets.

Gigascience *4*, 7.

99. Loh, P.R., Danecek, P., Palamara, P.F., Fuchsberger, C., Reshef, Y.A., Finucane, H.K.,
Schoenherr, S., Forer, L., McCarthy, S., Abecasis, G.R., et al. (2016). Reference-based
phasing using the Haplotype Reference Consortium panel. Nat. Genet. *48*, 1443–1448.

100.Fuchsberger, C., Abecasis, G.R., and Hinds, D.A. (2015). Minimac2: Faster genotype
imputation. Bioinformatics *31*, 782–784.

101.Tareen, A., and Kinney, J.B. (2020). Logomaker: beautiful sequence logos in Python.
Bioinformatics *36*, 2272–2274.

102.Reynisson, B., Alvarez, B., Paul, S., Peters, B., and Nielsen, M. (2020). NetMHCpan-4.1
and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent
motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res.
48, W449–W454.

103.Vita, R., Blazeska, N., Marrama, D., IEDB Curation Team Members, Duesing, S.,
Bennett, J., Greenbaum, J., De Almeida Mendes, M., Mahita, J., Wheeler, D.K., et al.
(2025). The Immune Epitope Database (IEDB): 2024 update. Nucleic Acids Res. *53*,
D436–D443.

104.Hanssen, F., Garcia, M.U., Folkersen, L., Pedersen, A.S., Lescai, F., Jodoin, S., Miller,
E., Seybold, M., Wacker, O., Smith, N., et al. (2024). Scalable and efficient DNA
sequencing analysis on different compute infrastructures aiding variant discovery. NAR
Genom. Bioinform. *6*, lqae031.

105.McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A.,
Garimella, K., Altshuler, D., Gabriel, S., Daly, M., et al. (2010). The Genome Analysis
Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data.
Genome Res. *20*, 1297–1303.

106.Verbanck, M., Chen, C.-Y.Y., Neale, B., and Do, R. (2018). Detection of widespread
horizontal pleiotropy in causal relationships inferred from Mendelian randomization
between complex traits and diseases. Nat. Genet. *50*, 693–698.

107.Huang, Y., McCarthy, D.J., and Stegle, O. (2019). Vireo: Bayesian demultiplexing of
pooled single-cell RNA-seq data without genotype reference. Genome Biol. *20*, 273.

108.Neavin, D., Senabouth, A., Arora, H., Lee, J.T.H., Ripoll-Cladellas, A., sc-eQTLGen
Consortium, Franke, L., Prabhakar, S., Ye, C.J., McCarthy, D.J., et al. (2024).
Demuxafy: improvement in droplet assignment by integrating multiple single-cell
demultiplexing and doublet detection methods. Genome Biol. *25*, 94.

109.Wolf, F.A., Angerer, P., and Theis, F.J. (2018). SCANPY: large-scale single-cell gene
expression data analysis. Genome Biol. *19*, 15.

110.Domínguez Conde, C., Xu, C., Jarvis, L.B., Rainbow, D.B., Wells, S.B., Gomes, T.,

Howlett, S.K., Suchanek, O., Polanski, K., King, H.W., et al. (2022). Cross-tissue
immune cell analysis reveals tissue-specific features in humans. Science *376*.
https://doi.org/10.1126/science.abl5197.

111.Kang, J.B., Nathan, A., Weinand, K., Zhang, F., Millard, N., Rumker, L., Moody, D.B.,
Korsunsky, I., and Raychaudhuri, S. (2021). Efficient and precise single-cell reference
atlas mapping with Symphony. Nat. Commun. *12*, 5890.

112.Gabernet, G., Marquez, S., Bjornson, R., Peltzer, A., Meng, H., Aron, E., Lee, N.Y.,
Jensen, C.G., Ladd, D., Polster, M., et al. (2024). nf-core/airrflow: An adaptive immune
receptor repertoire analysis workflow employing the Immcantation framework. PLoS
Comput. Biol. *20*, e1012265.

113.Sturm, G., Szabo, T., Fotakis, G., Haider, M., Rieder, D., Trajanoski, Z., and Finotello,
F. (2020). Scirpy: a Scanpy extension for analyzing single-cell T-cell receptor-
sequencing data. Bioinformatics *36*, 4817–4818.

114.He, L., Davila-Velderrain, J., Sumida, T.S., Hafler, D.A., Kellis, M., and Kulminski, A.M.
(2021). NEBULA is a fast negative binomial mixed model for differential or co-
expression analysis of large-scale multi-subject single-cell data. Commun Biol *4*, 629.

115.Wu, T., Hu, E., Xu, S., Chen, M., Guo, P., Dai, Z., Feng, T., Zhou, L., Tang, W., Zhan,
L., et al. (2021). clusterProfiler 4.0: A universal enrichment tool for interpreting omics
data. Innovation (Camb.) *2*, 100141.

116.Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., Zheng, S., Butler, A., Lee, M.J.,
Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-
cell data. Cell *184*, 3573-3587.e29.

117.Massoni-Badosa, R., Aguilar-Fernández, S., Nieto, J.C., Soler-Vila, P., Elosua-Bayes,
M., Marchese, D., Kulis, M., Vilas-Zornoza, A., Bühler, M.M., Rashmi, S., et al. (2024).
An atlas of cells in the human tonsil. Immunity.
https://doi.org/10.1016/j.immuni.2024.01.006.

118.Nouri, N., and Kleinstein, S.H. (2018). A spectral clustering-based method for identifying
clones from high-throughput B cell repertoire sequencing data. Bioinformatics *34*, i341–
i349.

119.Housley, W.J., Fernandez, S.D., Vera, K., Murikinati, S.R., Grutzendler, J., Cuerdon, N.,
Glick, L., De Jager, P.L., Mitrovic, M., Cotsapas, C., et al. (2015). Genetic variants
associated with autoimmunity drive NFκB signaling and responses to inflammatory
stimuli. Sci. Transl. Med. *7*, 291ra93.

120.Wang, Y.-F., Zhang, Y., Lin, Z., Zhang, H., Wang, T.-Y., Cao, Y., Morris, D.L., Sheng,
Y., Yin, X., Zhong, S.-L., et al. (2021). Identification of 38 novel loci for systemic lupus
erythematosus and genetic heterogeneity between ancestral groups. Nat. Commun. *12*,

772.

121. Ishigaki, K., Sakaue, S., Terao, C., Luo, Y., Sonehara, K., Yamaguchi, K., Amariuta, T.,

Too, C.L., Laufer, V.A., Scott, I.C., et al. (2022). Multi-ancestry genome-wide

association analyses identify novel genetic mechanisms in rheumatoid arthritis. Nat.

Genet., 1–12.

122. Consortium, T.G. (2020). The GTEx Consortium atlas of genetic regulatory effects

across human tissues. Science *369*, 1318–1330.

Figure 1

Figure 2

Figure 3

A OR=2.35, p=0.033

5.26% 11.54%
(9/171) (27/234)

B
Literature Search
PubMed (Inception to 2025)
Keywords: 'multiple sclerosis', 'Epstein-Barr
virus', 'PCR', 'viral load'

Inclusion Criteria
Peer-reviewed original research
EBV DNA in blood (qPCR)
MS patients and healthy controls

Data Restriction
EBV DNA Positivity within 5-75%

Meta-analysis

C

Study	Odds Ratio	OR	95%-CI
Hon et al.		0.97	[0.13; 7.33]
Pandit et al.		1.05	[0.35; 3.20]
Lindsey et al.		1.10	[0.59; 2.05]
Agostini et al.		1.25	[0.55; 2.86]
Lucas et al.		1.47	[0.88; 2.45]
Wagner et al.		2.13	[0.76; 5.95]
Agostini et al.		2.19	[1.22; 3.95]
Ours		2.35	[1.07; 5.13]
Ramroodi et al.		2.99	[1.65; 5.43]
Cocuzza et al.		3.09	[1.24; 7.68]
Salehi et al.,		4.53	[0.83; 24.76]
Common effect model		1.85	[1.48; 2.33]
Random effects model		1.84	[1.39; 2.45]

Heterogeneity: I^2 = 11.0%,
τ^2 = 0.0197, p = 0.3395

0.1 0.5 1 2 10

Odds Ratio (EBV DNA positivity in MS vs Control)

Figure 4

Figure 5

Figure 6

EBV Detection and GWAS

409,331 participants across the US
(Multi-ancestry)

313,774 participants across the UK
(Europeans)

Whole Blood
(723,105)

Saliva
(48,899)
(not used for GWAS)

Short Read Whole
Genome sequence

SNV/indel call

Quantification of
reads mapped on
EBV genome

Association test
Ancestry/Age/Gender

PheWAS

EBV DNA GWAS
(DNA positivity/DNA load)
   Europeans (METAL)
   Multi-ancestry (MR-MEGA)

Figure S1

A

B EBV Positivity

C EBV Load

Figure S2

A

B

Figure S3

A

Gene Overlap among MS-Related Traits

MS

EBV Load

MS Progression

5   11   4

OR = 35.05   OR = 0
p = 1.41x10⁻⁶   P = 1

B   **C**

D

E

Figure S4

A

B

C

Figure S5

Figure S6

Figure S8

Figure S9

Figure S10

Standard pipeline

10x reads (fastq) ⟶ Cell Ranger
(human + EBV reference) ⟶ gene count
(human + EBV)

2step strategy (VIRTUS3)

10x reads (fastq) ⟶ Cell Ranger
(human reference) ⟶ gene count
(human)

⟶ unmapped read ⟶ Alevin
(EBV) ⟶ gene count
(EBV)

Figure S11

Figure S12

A

predicted.celltype.l1

- Activated Naive B
- CD4 T
- CD8 T
- Cycling B
- Cycling T
- Cycling follicular dendritic
- Cycling myeloid
- Dendritic
- Double negative T
- Epithelial
- Follicular dendritic
- Germinal center B

- Granulocytes
- Innate lymphoid
- Mast
- Memory B
- Monocyte/macrophage
- Naive B
- Naive CD4 T
- Naive CD8 T
- Natural killer
- Plasma
- Plasmacytoid dendritic

B

total_counts_EBV

Figure S13

Figure S14